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Summary
The adaptive immune response is crucial for defence of organisms against infections. There are two
main cell populations of the adaptive immune system, T and B lymphocytes, bearing specific receptors
which allow to recognise infection and cancer antigens. Although these cells may play a beneficial
role in viral or bacterial infection, in some cases, like autoimmune diseases or organ transplantation,
T and B cell responses are undesired.
Chronic graft rejection is associated with the production of donor-specific antibodies by B cells, and
is the main reason for late graft failure. Immune cell clusters called tertiary lymphoid organs (TLOs),
which develop at chronic inflammation sites, are shown to be related to graft rejection in mice. The
stability of these clusters depends on the interactions of lymphocytes with stromal cells via chemokine
and cell surface proteins, which is modelled in chapter 3. Besides analytical approach, I implemented
a 3D agent-based off-lattice model, which allows to describe cell migration, chemokine diffusion and
receptor internalisation dynamics. I show that chemokine degradation by proteolysis does not influ-
ence its concentration in the vicinity of a secreting cell. In addition, I study how consumption of the
chemokine may change its gradient or even invert it at certain model parameters. Such a framework
might help in planning of therapies aimed to destabilize TLOs structure.
In chapter 4, I model interaction of germinal centres (GCs). GCs are organized clusters of immune
and stromal cells in secondary and tertiary lymphoid tissue, which are responsible for the generation
of B cell clones producing high affinity antibodies. Injected antibodies are shown to mask antigen
which is presented to B cells in GCs. It motivates to consider GCs as a system of agents interacting
via antibodies. Simulation of a system of interacting GCs suggested the possibility for early GCs to
suppress development of the later ones. I hope to provoke new experiments in order to investigate
influence of antibodies on the GC reaction course more precisely, which might help to regulate GC
responses in different clinical conditions.
Besides antibody responses, a cytotoxic T cell (CTL) activity might also find application in clinics.
In chapter 5, I estimated killing rates for CTLs in different experimental set-ups. Using the data from
in vivo microscopy about target cell fate depending on the contacts with CTLs I show that previous
contacts dramatically increase the probability of target cells to die. This kind of modelling may be
used for optimization of T cell-based therapies.
Zusammenfassung
Die adaptive Immunantwort ist essentiell für die Verteidigung des Organismus gegen Infektionen.
Es gibt zwei wesentliche Zellpopulationen des adaptiven Immunsystems, die T- und B-Lymphozyten,
welche spezifische Rezeptoren tragen, die ihnen erlauben, Antigene in Infektionen und Krebs zu erken-
nen. Obwohl diese Zellen bei viralen oder bakteriellen Erkrankungen hilfreich sind, ist die T- und B-
Zell Immunantwort unter bestimmten Bedingungen wie Autoimmunerkrankungen oder Organtrans-
plantationen unerwünscht.
Chronische Transplantatabstoßung geht mit der Produktion spezifischer Antikörper gegen das
Spendergewebe einher und ist der Haupgrund für spätes Transplantatatversagen. Verbünde von Im-
munzellen, genannt tertiäre lymphoide Organe (TLO), die sich an chronischen Entzündungsherden
bilden, stehen mit der Transplantatabstoßung in Mäusen im Zusammenhang. Die Stabilität dieser
Zellverbünde hängt von über Chemokine und Oberflächenproteine vermittelten Interaktionen ab, die
in Kapitel 3 modelliert werden. Neben einem analytischen Ansatz habe ich ein dreidimensionales
agentenbasiertes Off-lattice-Modell implementiert, das es uns erlaubt, die Zellmigration, Diffusion
von Chemokin und die Dynamik der Rezeptorinternalisierung zu beschreiben. Ich zeige hier, dass die
Degradation von Chemokin durch Proteolyse dessen Konzentration in der Umgebung einer chemok-
inproduzierenden Zelle nicht beeinflusst. Weiterhin untersuche ich, wie der Verbrauch von Chemokin
dessen Gradienten unter bestimmten Modellparametern verändern oder sogar umkehren kann. Dieses
Framework kann in der Planung von Therapien helfen, die darauf abzielen, TLO-Strukturen zu desta-
bilisieren.
In Kapitel 4 modelliere ich Interaktionen zwischen Keimzentren (GC). GC sind organisierte Ver-
bünde von Immun- und Stromazellen in sekundärem und tertiärem lymphoiden Gewebe, die für die
Bildung von B-Zell-Klonen verantwortlich sind, die hochaffine Antikörper produzieren. Es konnte
nachgewiesen werden, dass injizierte Antikörper das im GC den B-Zellen präsentierte Antigen be-
decken. Dies legt nahe, GC als ein System von interagierenden Akteuren zu betrachten. Simulationen
eines Systems interagierender GC weisen darauf hin, dass früh gebildete GC sich später bildende GC
unterdrücken könnten. Ich hoffe, damit Anregungen für neue Experimente zu geben, um den Einfluss
von Antikörpern auf die Keimzentrumsreaktion genauer zu untersuchen und damit möglicherweise
eine Regulation der GC Antwort unter verschiedenen klinischen Bedingungen zu unterstützen.
Neben der Antikörperantwort kann auch die Aktivität cytotoxischer T-Zellen (CTL) für die klin-
ische Anwendung relevant sein. In Kapitel 5 schätze ich die Rate ab, mit der CTL in verschiedenen
Experimenten Zellen eliminieren. Anhand von mittels in vivo-Mikroskopie generierten Daten zur weit-
eren Entwicklung von Zellen abhängig von der Zahl der Kontakte mit CTL weise ich nach, dass ein
früherer Kontakt mit CTL die Wahrscheinlichkeit für eine Zelle massiv erhöht, bei einem erneuten
CTL-Kontakt zu sterben. Dieser Modellierungsansatz könnte für die Optimierung von auf T-Zellen
basierten Therapien genutzt werden.
Contents
Contents v
1 Introduction 1
1.1 The immune system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.5 Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Secondary and tertiary tissue formation 5
2.1 Lymphoid tissue anatomy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 SLO structure and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3 Tertiary lymphoid tissue and chronic inflammation . . . . . . . . . . . . . . . . . . . . . 15
2.4 TLO in disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3 Modelling of tertiary lymphoid organs 21
3.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.2 Framework for TLO modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.2.1 Collision detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.2.2 Chemokine diffusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.2.3 Receptor dynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.2.4 Cell migration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.2.5 Stromal cell activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.2.6 Implementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.3 Simulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.3.1 Stochastic modelling of signal integration for a single stromal cell . . . . . . . . . 39
3.3.2 Contact frequency in perivascular space . . . . . . . . . . . . . . . . . . . . . . . 42
3.3.3 Chemokine gradient profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.3.4 Gradient inversion due to receptor internalization . . . . . . . . . . . . . . . . . . 55
3.3.5 Simulation of lymphocyte clustering . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4 Modelling of germinal center interactions 64
4.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.2 Mathematical model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5 Quantification of virus-specific CD8 T cell killing efficiency in vivo 80
5.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.2 Mathematical Model and Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
v
6 Summary and Outlook 86
A Analysis of GC size in spleen samples 89
Bibliography 92
Acronyms 107
List of Tables 110
List of Figures 111
1Introduction
1.1 The immune system
To cope with infection, organisms developed a special system of cells and molecules called the immune
system. The systems performs a layered defence, starting from nonspecific physical barriers like skin
to pathogen specific response such as antibody-mediated immunity. The innate immune system is re-
sponsible for the immediate non-specific responses. Surface barriers impede entrance of pathogens and
mechanical mechanisms like coughing and flushing (tears) help to get rid of microorganisms. Chemi-
cal barriers like antimicrobial peptides and decreased pH of the skin suppress growth of bacteria. The
complement system consists of a cascade of proteases which is activated upon the binding to antibody
and results in destruction of the cell membrane as well as opsonisation of the microbe and subse-
quent phagocytosis by immune cells. Cellular components of the innate system are phagocytic cells like
macrophages, neutrophils and dendritic cells. They are able to migrate to the infection site, search and
eliminate pathogens, secrete regulatory molecules which kill pathogens or provide signals to other cells.
During evolution, multicellular organisms developed a very complex defense system, and in jawed
vertebrates the immune response can be shaped by the environment thanks to its recombination-based
receptors system. This part of the immune system is called adaptive immune system and is responsible
for the more strong and specific responses partially because of the mechanism of the immune memory.
The major types of the cells are B and T lymphocytes. T cells have two main subtypes: the killer and
the helper T cells. Killer T cells specifically recognize antigen but only in the context of bound major
histocompatibility complex (MHC) and having contacted an infected cell they produce cytotoxins and
induce apoptosis of the contacted cell. Helper T cells do not possess any cytotoxic activity, but regulate
the response by signalling to other immune cells.
B cells are able to recognize antigen without any preprocessing and secrete antibodies which specif-
ically bind to pathogens and mark them for phagocytosis or induce complement response.
The primary immune organs, bone marrow and thymus, are responsible for generation of lympho-
cytes and early clonal selection. Selection of the best affine B cell clones during adaptive immune
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response takes place in structures called germinal centres (GCs) which are located in secondary lym-
phoid organs (SLOs) like lymph nodes and spleen.
Chronic inflammation induced by infection, cancer or organ transplantation may result in develop-
ment of new immune organs at the inflammatory site. This type of organs is called tertiary lymphoid
organs (TLOs). They are characterised by less organisation in their structure in comparison to SLOs and
are supposed to be a transient phenomenon, i.e. they dissolve upon inflammation resolution. Although
their presence was shown to be protective in viral infection, in autoimmune diseases or in chronic in-
flammation in transplanted graft they were shown to be a source of tissue specific antibodies and might
contribute to the pathological immune response.
1.2 Aim
In this work I consider several types of immune responses. I start with the review of secondary and
tertiary lymphoid organs structure and describe the model of TLO development in the following chapter.
Since TLOs may contribute to the disease pathology, investigation of stability of this structures is of
interest for fundamental as well as clinical research. Cell organisation in TLOs depends on chemokine
secretion and its gradient sensing. Description of this phenomenon may help to investigate in which
range of parameters the cluster formation is possible. Another important factor of TLO formation is cell
interaction via contact as reviewed in the next chapter. That is why the spatial aspect, i.e. relative cell
position in tissue, also influences the frequency of interaction, and, consequently, the probability to get
activated. I aim to construct a framework for modelling cell interaction via diffusing chemokines and
cell contacts which can describe chemokine distribution and ability to sense its gradient as well as to
model cell migration and contacts.
GCs located in follicles in SLOs and in matured TLOs are responsible for specific antibody response
which may contribute to the autoimmune disease pathology or may help to fight the infection. Usually
GCs are commonly considered to be individual structures and the internal mechanisms of antibody
affinity maturation are investigated. However, recently it was shown that there is a possibility of their
interaction via secreted antibodies, hence GCs may be treated as a system of interacting agents. The
aim of our study is to model such interaction and to investigate how they might change the kinetics of
affinity maturation depending on system size and starting time of development.
Finally, the third topic of our study is kinetic analysis of effector T cell responses. Adoptive T
cell therapy is a very promising clinical approach to treat infection diseases or cancer. It involves ex
vivo expansion of killer T cells specific to the target antigen and transfer of this cells into a patient.
Knowledge about the killing abilities of the T cells might help in estimation of cell amounts needed
for the therapy. However, there is no consent about the magnitude of the killing rate characterising
T cells and I aim to estimate this parameter for the in vivo system. The initial data were generated
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by two-photon microscopy observation lymph node extracted from infected mice. The populations of
infected cells were estimated for different T cell densities after one day experiment. In addition, based
on the cell contact data I was going to analyse how multiple interactions with T cells influences survival
probability of infected cells.
1.3 Methods
The methods, which are used, vary depending on the system and the aim of the problem. For early TLO
development events I chose a multiscale agent-based approach to describe spatial cell and molecule
distribution and their interactions, because the phenomena happening in the system range from molec-
ular to cellular scale. In order to achieve this, one needs to describe cell contacts, which demands the
implementation of a collision detection algorithm. Chemokine diffusion can be described by a diffusion
equation, represented by so-called partial differential equation (PDE). In the model migrating cells nav-
igate by sensing the difference of bound receptors at their surface and I implemented receptor dynamics
using ordinary differential equations (ODE).
In the model of GCs interaction I neglected spatial distribution patterns of cells and molecules and
used an ODEs system to describe cell population dynamics, antibody production, and binding to the
antigen.
In the same manner, T cell killing kinetics are simple to describe using a single ODE which was used
estimate killing rate for the experimental conditions. Data about cell contacts were used to test the
hypothesis of independence of cell death from previous interactions using a probabilistic model for cell
death events.
1.4 Results
In this work I constructed a framework for a 3D agent-based simulation. I implemented collision de-
tection, diffusion solver and receptor dynamics at cell surfaces. Such a framework is interesting not
only for our present problem in the context of TLO development but also for similar systems where cell
migration is governed by secreted chemokines which can be internalized after binding to a receptor.
Using an analytical solution and simulations based on the framework, I estimate how chemokine se-
cretion rate, receptor density at the cell surface and degradation rate contribute to chemokine gradient
generation. For a given range of receptor densities, cells may decrease chemokine concentration due
to receptor internalization, but an increase in receptor number compensates their sensitivity for a gra-
dient generated by a point source. Based on estimation of degradation rates from similar works, it was
shown that proteolytic degradation does not substantially change the chemokine concentration at the
distances comparable with the cell cluster size.
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In simulations of lymphocyte influx from a blood vessel to the tissue compartment, it was investi-
gated how contact frequency of tissue cells with lymphocytes varies with cell distance from the vessel.
By introducing an abstract signal integration to the model, I implemented activation of stromal cells in
tissue upon the contacts and how the probability to activate depends on the influx of lymphocytes.
In the context of interacting GCs, a measure for in silico comparison of immune responses was
introduced, which was used to show that early GCs suppresses the responses of the later ones. In
the same manner, the synchronous start of GC reactions appeared to generate more efficient immune
responses than if GC reactions start sequentially with a delay.
In the study of T cell killing kinetics, I estimated the killing rate of T cells in the experimental system
for several conditions. Using the data about target cell survival after different number of contacts with
the T cells, I showed that the probability of the death depends on the previous contacts and dramatically
increases after the third contact with a T cell.
1.5 Outlook
In this study I developed a framework which could be interesting to use for other systems and in the
context of TLO development, especially if additional experimental data can be integrated. Although
it still represents a rather simplistic view of the biological system, especially in the lack of known
information about mechanisms governing TLO development in graft transplants, it may be useful for the
estimation of therapeutic concentration of agents directed against receptors or chemokines participating
in cell positioning in order to destabilize the system.
The GC interaction model provokes experimental investigation of mutual influence of GCs and could
be tested in, for example, animal models of local immunization where an organism is sensitized to the
antigen sequentially in different body parts and GC kinetics are then compared. Such experiments will
help to validate the model of antibody feedback more precisely and directly estimate a contribution of
antibody feedback in GC interactions and kinetics of affinity maturation.
The same framework used for 3D modelling of cell interactions in TLO can be applied to a system
of effector T cells and infected target cells. The data on the probability of cell death depending on
the contact number can be integrated into the model in order to estimate the contribution of multiple
interactions with the T cells to the killing kinetics.
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2Secondary and tertiary tissue formation
2.1 Lymphoid tissue anatomy
Lymphocyte development, maturation and activation is performed in distinct anatomical tissues. There
are two types of lymphoid tissue: primary (generative) and secondary (peripheral) organs [1].
Bone marrow and thymus represent the primary lymphoid tissue where generation and maturation
of lymphocytes occur. Bone marrow is a source of all blood cells which are derived from hematopoetic
stem cells and can differentiate to any lineage of the innate or adaptive immune system. Also, the bone
marrow serves as a niche for antibody-producing B cells. The thymus is responsible for maturation of
T lymphocytes. There, T lymphocytes, also called thymocytes, interact with thymic epithelial cells and
are subjected to positive and negative selection. First, T cells must be able to interact with self-MHC
complex, but cells with high affinity of interaction with dendritic cells are eliminated in order to avoid
autoimmune responses.
Mature lymphocytes circulate between blood and secondary lymphoid organs such as lymph nodes
and spleen, where they can get activated upon the contact with antigen.
Lymph nodes are collections of lymphoid tissue which are usually located at the junctions of large
lymphatic vessels. Lymph nodes are oval-shaped anatomical structures covered with the lymph node
capsula, which consists of connective tissue, fig. 2.1. The interior of the lymph node is divided into outer
cortex and inner medulla. The cortex consists of B cell follicles without (primary follicles) and with
developed germinal centres (secondary follicles). Germinal centres are anatomical structures located in
lymph node follicles in which B cells are subjected to extensive proliferation, somatic hypermutations
and selection. Upon the interaction between T follicular cells and B cells in GCs, memory B cells
are generated which can boost the antibody response if the organism encounters the same antigen
in the future. The interior part of the cortex, called paracortex, contains predominantly T cells and
dendritic cells (DCs) and presentation of the antigen to T cells results in generation of memory T
cells. The medulla is the inner part of lymph nodes and it serves as an exit point for lymphocytes.
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Source:https://upload.wikimedia.org/wikipedia/commons/c/c7/2207_Structure_and_Histology_of_a_Lymph_Node.jpg
Figure 2.1: Schematic representation of a lymph node.
Also it contains medullary cords, where antibody-secreting plasma cells reside. The lymph flows out
of lymph nodes through medullary sinuses into efferent lymphatic vessels. Lymph nodes represent a
specific environment where lymph is filtered and scanned for different antigens allowing to generate an
efficient adaptive immune response. Every day, around 2 litres of lymph recirculates to the blood [1].
Spleen is a large organ of secondary lymphoid tissue which plays a major role in responses to antigen
in bloodstream as well as participates in iron metabolism, thrombocyte storage and hematopoesis [161].
The spleen consists of red pulp, white pulp and the marginal zone in between. The red pulp includes half
of the body monocytes [195] and is also populated with old red blood cells which are to be destroyed
[161]. The blood enters the spleen via the splenic artery which constitutes approximately 5% of total
cardiac output [69]. The splenic artery branches to trabecular arterias and, further, to central arteriols
which are surrounded by the T cell-rich periarteriolar lymphoid sheath (PALS). Antigen, being trapped
in the marginal zone, is transported by dendritic cells to PALS and presented to T cells. Marginal zone B
cells are responsible for antigen transfer to the follicles. In the white pulp some of B cells are organized
in primary follicles and where they surround clusters of follicular dendritic cells (FDCs) [69]. During
the immune response, GCs are generated in the follicles similar to the responses in the lymph nodes.
Tertiary lymphoid organs (TLOs) represent organisation of lymphoid tissue due to chronic inflam-
matory conditions. Such structures of immune cells are observed in cancer, infection and autoimmune
diseases and they vary in their form and cell content. The precise definition of TLO is still unclear and
I discuss it in more details in this introduction later. Similar to the lymph nodes, TLOs consist of two
distinct B and T cell zones and may include GCs which produce plasma cells with affinity to antigens
in the locality of TLOs. Their function is usually considered in the context of disease and, depending
on the conditions, TLO may be beneficial or detrimental. The formation of these structures is strongly
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connected to stromal cells which may change their phenotype due to signals from immune cells and
they create the microenvironment for immune cell homing. TLOs are considered as transient structures
and after inflammation resolution, for example, viral infection clearance, they are supposed to dissolve
as well.
There are other types of lymphoid organs such as mucosal- gut- and bronchus associated lymphoid
tissue (MALT, GALT and BALT, respectively), which are referred to as SLOs but are less organized
structures than lymph nodes or spleen and may be compared with TLOs as well.
2.2 SLO structure and development
Before we discuss the formation of TLOs, it is natural to give an overview of the main events and cells
participating in SLO development and maintenance, since they share some structural similarities and
TLO can be considered as an attempt to form SLO in non-predefined niche. From the structure and
functioning of lymph nodes discussed in the previous section one can see that SLO has two major com-
ponents, namely, stroma environment and immune cells. Their interactions are important for proper
immune response, for example, antigen delivery and presentation events and, as a result, activation of
different lymphocyte types. This is possible due to the specific environment created by stromal cells
such as networks of follicular dendritic cells and fibroblastic reticular cells. They are responsible for
immune cell positioning via chemokine secretion and providing survival and activation signals to the
immune cells. Here, I will review in more details the role of different cell types participating in SLO
development and structure maintenance.
Lymphatic tissue inducers cells (LTis) are responsible for the interaction with stromal cells to in-
duce expression of chemokines for immune cell positioning. The origin and function of this type of
cells is very well reviewed in [29, 115]. LTis are characterised by expression of CD4+CD3− and their
development is dependent on transcription factors RORγt, Id2, Ikaros, Tox and ligand-receptor pair
RANKL-RANK [7, 53, 56, 72, 226]. LTis express chemokine receptors CXCR5 (for CXCL13 ligand) and
CCR7 (for CCL21 and CCL19 ligands) and can be divided into 3 classes (CXCR5+CCR7− at B follicle
region, CXCR5+CCR7+ the boundary of B and T zones, CXCR5−CCR7− at T zone stroma) [114]. Since
LTis have CXCR5 receptor, they were shown to migrate to the lymph node environment which consists
of CXCL13 secreting stromal cells [210].
LTis provide a signal to stromal cells through lymphotoxin receptor LTβR by LTα1β2 molecule which
activates NF-κB transcription factors resulting in expression of adhesion molecules and chemokines
responsible for SLO homoeostasis, fig. 2.2. Another possible function of LTis is the maintenance of
epithelial integrity due to their production of IL-22 [198]. TLis are attracted to the intestinal epithelium
by CCL20 because of their expression of the CCR6 receptor and make clusters in cryptopatches. The
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Figure 2.2: Interactions between stromal and immune cells during lymphoid tissue de-
velopment. Retinoic acid produced by neural tissue induces chemokine secretion by stro-
mal cells (a) what attracts LTis cells. Interaction via TNF and LTα1β2 between LTis and
stroma results in increase of chemokine expression and expression of adhesion molecules
by stromal cells (b). Lymphocytes recruited by chemokines further contribute to LTα1β2
signalling to the stromal cells (c).
cryptopatches give rise to isolated lymphoid follicles, where LTis cluster with dendritic cells and interact
with B cells invoking T-cell independent IgA class switching [208].
In summary, LTis cells are important for SLO development and serve as activators of stromal cells
inducing expression of chemokines and adhesion molecules which are important in SLO homoeostasis.
Lymphatic tissue organizers (LTo) are cells of mesenchymal origin. Much less is known about
the development of this type of cells and about their precursors in comparison to the LTis. LTo are
charachterised as VCAMhighICAMhighMAdCam-1+ cells, the phenotype which stromal cells gain upon LT
βR signalling. It was shown in in vitro experiments with mesenchymal stem cells that TNFα or LTα1β2
8
Figure 2.3: Model of stroma differentiation according to [182].
was sufficient to upregulate VCAM, ICAM or MAdCAM-1 [11]. LT-dependent signal is delivered by LTis
cells, which are attracted to the chemokine CXCL13. The secretion of CXCL13 is initiated by the retinoic
acid produced by the neuronal tissue [29], fig. 2.2.
LTo may differentiate to fibroblastic reticular cells (FRCs), FDCs, and, as later identified in [98],
marginal reticular cells (MRCs), fig. 2.3. NKX2-5+ and ISL1+ cells were shown to be precursors of
FDCs, FRCs and MRCs in spleen, but the origin of lymph node stromal cell remains unknown [35].
Fibroblastic reticular cells are typical fibroblast-like cells located in T cell areas. They govern cell
migration by secretion of CCL19, CCL21 and also express IL-7 which is important for T cell survival
[121, 131]. FRCs are responsible for construction of the conduit network, which is used for signal
molecules and antigen transport into lymph node [65]. They are characterised by their surface markers
PDPN+PDGFRα+CD31−CD45− [65] and represent 20-50% of non-hematopoetic cells in lymph nodes
[65]. In the spleen, FRC development depends on the LT interaction with B cells, which induce CCL21
and PDPN expression [154], although it is not necessary in case of lymph nodes. The differentiation
to FRCs requires signalling via TNF-RI and LTβR, similar to FDCs, but interactions with CD4+ T cells
is necessary [97]. FRCs appear at the same time with MRCs and FDCs and share signalling pathways
needed for their development. In [182] it is hypothesized that FRCs may originate from the same
precursors as MRCs.
Podoplanin (PDPN), a molecule expressed at the FRC surface, is responsible for FRC network con-
tractility and its inhibition results in loss of tension in the FRC network [4, 14]. Such a dense structure
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allows for DCs and T cells migrating within to be in constant contact with FRCs. PDPN can also interact
with CLEC2 (C-type lectin domain family 1 member b) on DCs, regulating their motility [3]. Interaction
via PDPN-CLEC2 with platelets results in release of sphingosine-1-phosphate (S1P) [88]. S1P is respon-
sible for the egress of immune cells from lymph nodes. It induces expression of adhesion molecules in
HEV cells which changes HEV permeability [88].
Prosurvival signals provided by FRC by IL-7 to T and DCs cells are important for lymph node main-
tenance, and double deficiency in CXCL13 and IL-7 receptors results in the loss of lymph nodes [128],
although CXCL13−/− lacks only certain types of lymph nodes [12]. FRCs participate in the regulation
of lymph node remodelling due to damage and support survival of LTis cells [159].
FRCs may play immunosuppressive role to prevent damage of lymph nodes during acute reactions
via production of nitrogen oxide which reduces proliferation of effector T cells [191]. Another way
of T cell response inhibition is presentation of self antigens by FRCs resulting in tolerance induction
by elimination of autoreactive T cell clones [66]. In certain types of lymph nodes FRC were shown to
induce T regulatory cells [46].
FRCs are an important cell type for SLO maintenance and immune response regulation. They pre-
dominantly influence T cell responses and organize the environment for DCs and T cell interaction and
survival.
Follicular dendritic cells are the stromal cells of B cell follicles, which are responsible for positioning
and sustaining of B cells in germinal centres (GC) and primary follicles. FDCs secrete CXCL13, a ligand
of the CXCR5 receptor on the B cell surface, present antigen-antibody complexes to B cells in GCs, and
produce IL-6, inducing antibody secretion [61, 104, 106].
FDCs appear in the first week after birth and presence of B cells is necessary for differentiation of
their precursors [48]. Recently it was found that perivascular progenitor cells may give rise for FDCs
[111]. These cells express Mgfe8 and Pdgfrb and are able to gain an FDC phenotype in vivo and in vitro.
The phenotype of FDCs and their precursors is described in table 2.1. Matured FDCs express at their
surface adhesion molecules MAdCAM and VCAM, and can be distinguished from other stromal cells by
expression of complement receptors CD35 and CD21 [86], which are used for antigen retention.
The differentiation of FDCs precursors depends on LT and TNF interactions [111]. Activation
through TNF-RI and LTβR results in NF-κB signalling (reviewed in [182]). There are two distinct
pathways, canonical and alternative, see fig. 2.4. The canonical pathway is activated by TNF signalling
resulting in activation of IKK2. However, interaction through LTβR invokes both, canonical and alter-
native pathways, i.e. also activating IKK1. Knock-out studies show that a deficiency in the alternative
pathway results in loss of FDCs, whereas the canonical pathway seems not to be crucial for FDC devel-
opment.
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perivascular preFDC marginal sinus preFDC matureFDC
mural markers:
PDGFRβ +++ + -
NG2 +++ - -
FDC-associated markers:
SDF1 ++ n.d. -
VCAM1 + + ++
ICAM1 ++ + ++
MAdCAM1 +/- + +
Mfge8 + + ++
CXCL13 + + ++
E-NPP2 ++ + ++
IGFBP3 + + +
Periostin +++ n.d. +
Clusterin +/- + +
BP-3 - + +
FcγRIIβ - +/- +
CD21/35 - - +
TNFR1 +++ + +
LTβR +++ + +
differentiation signals:
LTis cells, B cells LTαβ
B cells LTαβ, TNF
Table 2.1: Expression of markers during FDC maturation according to the model from
[111].
FDCs participate in SLO maintenance and functioning. The homeostatic chemokine CXCL13 is re-
sponsible for the positioning of B and T follicular helper cells, which bear the CXCR5 receptor, fig.2.5.
Disruption of the FDC network results in loss of spherical form by follicles, and cells become positioned
in so-called ’bands’ instead [217]. It is interesting that FDCs derived from lymph nodes are able to form
B cell clusters in vitro in contrast to FDCs of spleen origin [86].
Another function of FDCs is antigen presentation. Earlier FDCs were thought to be a subset of DCs
because of their appearance, but they were shown to be of mesenchymal origin. And although they
present antigen at the surface as DCs do, antigen is presented using the complement receptor of the Fc
receptor in the form of an immune complex, i.e. bound to antibody [8], while DCs use MHC (major
histocompatibility complex) molecules for this. Moreover, in contrast to DCs which present processed
antigen, i.e. in the form of peptide, FDCs do not process antigen before its presentation. The lifetime
for such complexes is not measured yet, but it may be estimated from antigen decay rate and is in the
order of years [200]. Such a long time probably could be explained by the process of antigen cycling:
C3d-coated immune complexes bound to CR2 are transported to endosomes [85], keeping antigen from
degradation. Opsonised intact complexes were still observed within FDCs after a period of 3 months
[86].
Antigen may be delivered to FDCs by several ways depending on its size. Small antigens (less than
70kDa) are transported via conduit network and can be trapped directly by FDCs themselves [16, 183].
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Figure 2.4: Activation of NF-κb alternative and canonical pathways and phenotype of
mice deficient in different components of the cascades.
Activation of NF-κb alternative and canonical pathways and phenotype of mice deficient in different
components of the cascades (as reviewed in [182]).
Bigger antigens are transported by other cells, namely, by SCS (subcupsular sinus) macrophages and
lymph node-resident DCs, which allows to isolate FDCs from unprocessed antigen [77, 165]. These
complexes are transported from DCs and SCS macrophages to naive B cells [165] and then they are
transferred to FDCs, which was shown in co-culture in vitro experiments [85]. Antigen presenting
function is crucial in germinal centres (GCs), anatomical structures inside of SLO, where B cells are
selected in order to generate high affine antibodies. FDCs located in the so-called light zone of the
GC are responsible for cognate interaction with B cells via B cell receptor (BCR) [213]. The germinal
centre reaction is discussed in more details in chapter 4. Although antibody responses with affinity
maturation were shown to exist even in the absence of FDCs [135], it required a high antigen load. If
antigen doses are low, presentation via immune complexes at FDCs is needed for the response to occur
[184]. Besides interaction via BCR, FDCs interact with B lymphocytes with adhesion molecules VCAM1
and ICAM1, which enhance signalling in B cells in vitro [33] and promote survival of GC B cells in co-
culture experiments [103, 216]. Impaired expression of adhesion molecules by FDCs results in reduced
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antibody affinity maturation in GCs [150, 176, 215, 216]. FDCs are capable to sense molecules of
microbial origin not only in the form of immune complexes, but via pattern recognition receptor TLR4,
which binds lipopolysacharides. Lack of this receptor in FDC results in reduced affinity maturation [70].
FDCs express molecules promoting follicular and GC B cell survival. BAFF expression by FDCs was
shown to be important for GC sustaining, and its deficiency leads to GC ablation [174]. In addition,
FDCs may influence B cell survival via signalling through Wnt, Sonic hedgehog (SHH) and Notch cas-
cades. This was shown in vitro for Wnt and Notch [118, 228] and hypothesized for SHH in [6] since B
cells and FDCs express SHH receptors and SHH is expressed by FDCs.
Another role of FDCs in GC is connected to marking apoptotic GC B cells, which accumulate during
GC reaction due to negative selection. It is very unfavourable for self-molecules to be released in the
area of the GC reaction in order to avoid generation of self-specific B cell clones, which is why there is
an efficient mechanism for removal of apoptotic material. FDCs secrete Mfge8 [109], a molecule that
interacts with phosphatidylserine which is exposed on the surface of apoptotic cell [83]. Tingible body
macrophages (TBM) recognize Mfge8 and engulf such cells [82].
In conclusion, FDCs are important players of lymphoid tissue which participate in its homoeostasis
and participate in the adaptive immune response in GCs by providing survival signals to B cells and
supporting elimination of apoptotic lymphocytes.
Marginal reticular cells, the stromal cells adjacent to subcapsular synus, are less studied stromal cell
phenotype. It is still not shown that LTo are precursors of MRC, but comparison of different expressed
markers points to this possibility [98, 182]. These cells express VCAM-1, ICAM-1, BP3, RANKL, CXCL13,
MAdCAM-1, where expression of the last two molecules depends on LT interactions, which was shown
in experiments with blocking of LTβR. However, contacts with B or T lymphocytes do not seem to be
necessary for MRC maturation [98]. In [182] it was concluded that MRC and FDC share common
differentiation pathways based on the phenotype of knock out animals (p52−/−, RelB−/−), where
deficient expression of CXCL13 was observed [31, 68, 168]. In comparison to MRCs, the maturation
of FDCs requires stimulus through TNF-RI in addition to LTβR, and MRCs may be considered as FDC
precursors, since MRCs were shown to be responsible for FDCs generation in lymph nodes [227]. It is
interesting to note that MRCs were not found at the sites of ectopic lymphoid tissue which limits their
functions to SLOs [26, 98].
LTis and LTo are central players in secondary lymphoid organ development, where LTo are responsi-
ble for expression of molecules crucial for lymphocyte homing and LTis are responsible for the activation
of stroma and seem to be a limiting factor [137].
Vascular cells organize molecular and cellular transport. There are two types of lymphatics: lym-
phatic vessels (LVs) and capillaries. Capillaries represent the smallest vessels which have highly perme-
able blind ends. Interstitial fluid enters the capillary due to interstitial pressure and is transported to
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Figure 2.5: FDC functions: positioning of GC and follicular B cells and T follicular cells
via chemokine secretion (a); immunological synapse formation with B cells using adhe-
sion molecules VCAM1 and ICAM1 (b); antigen presentation to GC B cells couples with ac-
tivation of CD40 (c); innate sensing of bacterial lipopolysaccharides via Toll-like receptor
resulting in upregulation of factors responsible for B cell survival, positioning and anti-
body class-switching (d); pro-survival signalling via BAFF secretion to B cells (e); marking
of apoptotic B cells with Mgfe8 to induce their clearance by tingible body macrophages
(TBM) (f). [6]
LVs, which are larger and have smooth muscle walls. These collecting LVs deliver fluid, or lymph, to
the right lymphatic duct and then afferent LVs bring it to the lymph nodes. Efferent LVs which go out of
lymph nodes may serve as afferent ones for another lymph node or may return lymph to the lymphatic
duct where it enters the blood.
LVs originate from the cardinal venule and separate from blood endothelial vessels after PDPN-
CLEC2 interaction with platelets [160]. LVs form a dynamic network which can be subjected to lym-
phangiogenesis during inflammation in order to regulate lymph circulation and to avoid excessive
swelling [92]. Transport function of LVs is important for the adaptive immune response, because they
are responsible for antigen delivery to lymph nodes in soluble form via lymph or by antigen-presenting
cells such as DCs and macrophages [29, 178]. Efferent (outgoing) LV cells express S1P ligand which
regulates cell egress from the lymph node and sustains homoeostasis of lymph nodes [164]. Similar to
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FRCs, LVs contribute to peripheral tolerance by persistently expressing and presenting tissue-restricted
antigens, but the exact mechanism is still unknown [67].
Another type of vasculature are high endothelial venules (HEV). Their function is to organize the
entrance of lymphocytes into lymph nodes from the blood. They express PNAd, a leukocyte adhesion
molecule, which slows leukocyte motion down and allows them to sense and follow chemokine gradi-
ents generated by the lymph node environment [194]. As for other cell types supporting SLO structure,
HEV need LTβR interaction for their development and sustainment [27, 158].
Summary on SLO development. There are two important cell types necessary for SLO development:
LTis and LTo cells. Activation of CXCL13 secretion by LTo may be stimulated by retinoic acid produced
by neural tissue. LTis are attracted to LTo cells due to expression of CXCR5 (receptor for CXCL13),
and can interact via LTαβ with LTo which might result in signalling via NFκB cascade and leads to
upregulation of CXCL13, CCL19, CCL21 needed for lymphocyte positioning and positive feedback loop
in CXCL13 expression, fig. 2.6. Interaction of LTo with immune cells induces their differentiation into
different stromal cell subpopulations such as FRCs and FDCs, which form network environments for
immune cell communication and perform other maintenance functions reviewed above. Interaction
in LT-dependent manner with immune cells regulates vascular endothelial growth in HEV, which are
responsible for lymphocyte trafficking. Such complex interaction between stromal and immune cells
allows to develop and maintain SLO organisation and to provide an environment for effective immune
responses.
2.3 Tertiary lymphoid tissue and chronic inflammation
SLOs represent an environment with a structure specialized for immune cell homing and the immune
response establishment. However, during conditions of chronic inflammation such as infection or trans-
plantation, so-called tertiary lymphoid organs may form. Since such structures do not have a predefined
position and environment formed during embryogenesis, and because they are observed at different
stages of their development, a definition is needed in order to distinguish immune cell infiltrate from
matured TLO. A good review on TLO development can be found in [153], and in [153] an immune cell
cluster is defined as TLO if
• it has two adjacent but anatomically distinct T an B cell compartments
• FRCs and PNAd+MECA79+ HEV are present in the T cell compartment
• stromal cell with FDC phenotype are found
• there are formed GCs populated with AID+ B cells
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Figure 2.6: Model of SLO and TLO development. At the early stage of SLO formation, in-
teraction between LTis and LTo results in chemokine and adhesion molecule expression by
LTo (a); lymphocytes recruited via developed HEV contribute to signalling to LTo cells (b);
LTo cells differentiate to FDCs and FRCs which govern lymphocyte migration via chemokine
production, B and T cell compartments appear(c). TLO development starts from inflam-
matory condition, where immune cells (DCs, T and B lymphocytes, macrophages (M)) are
recruited via inflamed blood vessel (BV) (d); in chronic inflammation lymphocytes play
a role of LTis by persistently delivering LTα1β2 signal (red dotes) to stromal cells (e);
stromal cells acquire FDC and FRC phenotype, endothelial cells get HEV-like phenotype;
chemokines and other factors secreted by stromal cells support lymphocyte survival and
compartmentalisation (f). 16
• class-switching is shown to happen in GC B cells.
Development of TLO shares the same signalling pathways as SLO. Lymphotoxin-dependent interactions
are obligatory for lymphoid organogenesis formation, since mice deficient in LTα lacks any SLOs. Trans-
gene expression of LTα in kidney and pancreas results in TLO formation in these tissues where not only
organized T and B cell clusters and the ability to develop specific immune responce were observed,
but also vessels with morphology of HEV were found [110]. The difference from SLO is that TLO do
not have predefined regions where activation of stromal cells is orchestrated by an initial signal from
neural tissue and with the help of LTis cells interacting with stroma via LT. In case of chronic inflam-
mation, other cell types expressing LTα1β2, such as B cells, NK cells or T lymphocytes are believed to
perform LTis function [10]. Although the importance of LT-interactions was reported in many condi-
tions, lymphoid neogenesis may be observed even in LTa−/− mice. In an influenza infection model,
CXCL13 and CCL21 chemokine production and iBALT formation were observed even in absence of TNF
or LT-dependent stimulation [148]. A possible explanation may be that lymphoid tissue neogenesis can
be activated via Toll-like receptors [10].
In TLOs, similar to SLOs, chemokines govern cell migration and their overexpression in different
model systems leads to lymphoid neogenesis. For example, lymph node-like structures were found if
expression of CCL21 in pancreas was transgenically induced [39]. However, it should be pointed that
it was not true for skin, hence it needs some tissue specific conditions. Overexpression of CXCL13 in
pancreas induced TLO with T and B cell zones and HEV [130]. In this study, TLO development did
not happen if LTαβ was blocked. Two other important chemokines, CCL21 and CCL19, responsible
for T cell positioning, did not induce TLO development upon being ectopically expressed, although
lymphocyte clustering was observed in this set up [129]. Relevance of SLO homeostatic chemokines
for TLO development is supported by analysis of their expression in different disease conditions. For
example, in rheumatoid arthritis, CXCL13 and CCL21 were associated with formation of organized
TLO-like cell aggregates [134]. Similarly, in autoimmune thyroid diseases, CXCL12, CXCL13 and CCL21
levels were higher in tissue specimens containing ectopic lymphoid structures. Moreover, expression of
these chemokines or their receptors is essential for ectopic lymphoid tissue formation. Loss of CCL21
and CCL19 resulted in impaired iBALT formation [179], and deficiency in receptor CCR7 or CXCR5
expression also disturbed development and organisation of TLO in chronic antigen-induced arthritis
mice [221]. Expression of the cytokine IL-7 seems to contribute to neogenesis as well. This molecule
is important for T cell homeoestasis as discussed earlier and its overexpression results in additional
lymph node development [153]. In rheumatoid arthritis patients expression of IL-7 is correlated with
LTβ expression in synovial tissue [203].
The stroma compartment is important for lymphoid organ maintenance and TLO were shown to
include developed reticular cell network and conduits [120]. The ability of stromal cell from certain
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tissue to gain a phenotype of LTo cells probably defines sites where TLO may be observed. For example,
meninges are fibroblast-rich tissue, and in patients with multiple sclerosis, fully developed B cell follicles
were observed inside this tissue, but never in white-matter lesions in spite of the presence of immune
infiltrate [189]. The ability of different cells types to gain an LTo phenotype was shown in several
works. Aorta smooth muscle cells expressed adhesion molecules VCAM1, ICAM1 and chemokines such
as CXCL13 upon LTβ and TNFR1 signalling [126]. In another study [111], perivascular cells were
shown to give rise to FDCs upon LT and TNF-dependent stimulation, which means that FDC precursors
are ubiquitous in the organism. But not only the location of chronic inflammation is important for TLO
development. It was shown that different types of infection results in different TLO structures. Mice
infected with MVA (Modified Vaccinia Ankara) developed in their lungs iBALT, containing stromal cells
producing CXCL12 and FDCs in B cell follicles [63]. In contrast, P. aeruginosa infection did not lead to
FDC development, although iBALT containing CXCL12+ cells were observed [64].
A positive feedback generated during stromal cell-lymphocyte interactions by secretion of CXCL13
attracting B cells and support of this stroma phenotype by lymphotoxin signalling makes it difficult to
dissect the role of immune and stromal cells in TLO organisation. However, it is interesting to note
that depletion of B cells via anti-CD20 therapy did not result in improvement in Sjögren syndrom, and
associated parotid lymphoma and BAFF overexpression were observed over the course of the disease
[171]. That implies an active contribution of stroma to chronic inflammation condition, hence stromal
cells may be considered as therapeutic targets.
Another cell type which was shown to contribute to TLO development are DCs, probably due to
their LTβ expression [73, 75]. Injection of DCs results in iBALT neogenesis, and DCs depletion reduced
the number of iBALT associated with influenza infection [75]. A similar effect was observed after DCs
depletion in mice infected with MVA, where iBALT size was reduced [80].
Summary of TLO development. TLO development has similarities to SLO development in terms of
events and cell types participating in its organization and maintenance, although the precise mechanism
is still unknown and may vary depending on the tissue and inflammation type. Lymphocytes recruited
to the chronically inflamed region may play the role of LTis cells and local stromal cells perform LTo
function, where the same signalling pathways via lymphotoxin seem to be used, fig. 2.6. The same
chemokines necessary for SLO homoeostasis were shown to be involved in TLO formation. Cytokines
such as IL-7 may also contribute to neogenesis. TLOs are considered as transient structures [167] in
contrast to SLOs and their stability is an interesting question for research.
2.4 TLO in disease
As discussed in the previous section, chronic inflammation may lead to TLO formation. Depending on
the conditions, the presence of TLO may have either positive or negative impact on the inflammation
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outcome.
An example of a beneficial role is lymphoid neogenesis during infection, where TLOs were shown
to play a protective role. Mice infected with influenza virus develop TLOs in lungs where B cells differ-
entiate to plasma cells specific to viral proteins [75]. Moreover, these structures are able to protect the
organism from the influenza infection even if SLOs are absent [147]. iBALT in lungs as well as ectopic
lymphoid structures in gut can attract B cells which produce IgA antibodies specific to influenza or inter-
stitial infections [153]. Spatial organisation of immune cells at the inflammatory sites via chemokines
produced in lungs is important for control of M. tuberculosis growth [102].
Although TLO may be associated with positive outcomes during chronic infections, their presence
in autoimmune disease is related to its severity. The molecules involved in TLO formation which were
discussed above, such as CXCL13, CCL21, CCL19 and LTα/β, were detected at sites of chronic inflam-
mation and the level of their expression is correlated with the degree of TLOs organisation [29]. Since
matured TLOs may include GCs in their structures, there is a risk of autoimmune B cell clone selection
during germinal centre reaction due to the high availability of disease specific antigen, for example,
nicotinic acetylcholine receptor in the case of myasthenia gravis or SBB/La (Sjögren syndrome antigen
B, autoantigen La) in the case of Sjögren syndrome [10]. Tightly regulated SLOs have mechanisms
which prevent entry of autoreactive B cells to GCs due to downregulation of CXCR5, a receptor for
CXCL13 [60]. TLOs lack this function and in rheumatoid arthritis, Sjögren syndrome and other autoim-
mune diseases, high-affinity autoreactive B cell clones were observed [167]. B cells in GCs from chronic
inflammation sites were shown to be subject to somatic hypermutations in patients with rheumatoid
arthritis and Sj`‘orgen syndrom. Impaired GC regulation may lead to aberrant clonal selection and neo-
plasia [29]. Lymphoma were observed predominantly in TLO but not SLOs during inflammation and,
for example, they can develop in H.pylori gastritis and Sjögren syndrome [20, 225].
Chronic infiltration by immune cells is also observed in cancer. However not every tumour type
may lead to TLO development. It is likely to depend on the expression of certain molecules, which
are also involved in TLO development, such as LTαβ, TNF, IL-1β, IL-6 [167]. Presence of LTO may be
associated with improvement. For example, TLOs are correlated with higher survival rate in patients
with hepatocellular carcinoma and with prolongation of metastasis free-survival in case of breast cancer
(reviewed in [192]). Although in some cases patients with developed immune response against a
tumour have a better prognosis and expression of such chemokines as CXCL13 and CCL19 was shown
to be beneficial [167], tumour infiltration by immune cells may invoke angiogenesis due to activation of
complement system or inhibit immune responses because of the recruitment of T regulatory cells. Hence
contribution of immune cells to cancer prognosis remains controversial [73, 180]. It is interesting to
mention the ability of B cells from tumour-associated TLOs to produce tumour specific antibodies not
only of IgG, but of IgA class as well [74], resembling T cell independent IgA-class switching in gut.
Antibody specificity may be connected with positive or negative outcomes depending on the antigen.
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For example, antibodies to XAGE1 and MUC1 are correlated with better survival what is not the case
for p53 [76, 181].
In transplantation, chronic inflammation and high alloantigen availability may promote immune
response against grafts. During chronic rejection, the inflammation is shifted towards the adaptive im-
mune response which may be accompanied by a gradual organisation of lymphocytes into TLOs [202].
Almost all human grafts (including kidney, lungs, heart), which were explanted due to their failure, har-
boured TLOs [201]. The extent of TLO contribution to graft failure is unclear, partially due to design of
the respective studies, because most of them are based on biopsies from already explanted transplants.
A tissue sample obtained during the biopsy represents only approximately 1/10000 part of the organ
in the case of a renal graft [201]. Hence it has its own limitations. However, characterisation of gene
expression in TLOs from chronically rejected kidney grafts showed that graft life expectancy depends on
how functional TLOs are [202]. Moreover, the repertoires of allospecific antibodies generated by cells
from TLOs and SLOs had minimal overlap, which means that the local immune response is separated
from SLO-mediated.
TLOs may be associated not only with rejection but with beneficial outcomes as well (recently re-
viewed in [91]). A tolerogenic role of TLOs was shown for lung transplants where a decrease in BALT
number was correlated with rejection, perhaps, because BALTs may contribute to the defence against
infection according to [90]. It seems that TLO which are rich in T regulatory cells may result in im-
munosuppression as it was shown in cancer and renal transplant patients [91].
The contribution of TLO to disease outcome varies among tissues and disease pathology. Lack of
direct evidence for the TLO contribution makes it difficult to conclude when TLO development is desired
or detrimental for the patient state.
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3Modelling of tertiary lymphoid organs
3.1 Background
TLO were shown to develop at chronic inflammation sites as discussed in the previous section. These
structures may contribute to disease outcome, which is why the problem of their formation and main-
tenance is very important for clinical implications. Although the whole complex mechanism underlying
lymphoid neogenesis is not known and seems to vary among different inflammatory conditions, I aim
to investigate B cell clustering in the context of renal graft transplants using mathematical modelling.
The presented model is rather general and can be considered as a framework which implements cell
migration, cell-cell interactions, chemokine diffusion and receptor dynamics at the cell surface, hence it
can be further applied for similar systems where cell clustering is observed and governed by chemokine
gradients.
B cells from TLOs in the context of cancer or chronic graft rejection were shown to produce antibod-
ies in situ which are specific to tumour antigen or to the donor HLA [73, 167]. In the case of cancer, B
cell presence may be correlated with worse outcome [52] in ovarian carcinoma. On the other hand, B
cells together with DCs may be involved in activation of CD4+ T cells and high density of B cells corre-
lates with increased survival [74]. And although in the case of cancer, the ability of B cells to present
antigen can be considered as beneficial, in the context of transplantation this is undesired. The role of
TLOs in transplant rejection is controversial and in primate studies their presence was shown to be not
predictive for the outcome, but this was concluded only for early rejection [96]. In the same studies,
TLO were more often found in samples with interstitial fibrosis and tubular atrophy, which means that
TLOs may have a role in graft damage.
B cell clusters may contribute to the pathogenesis not only by producing donor-specific antibod-
ies after germinal centre formation. The ability of B cells to play the role of antigen-presenting cells
may foster T cell responses, which was demonstrated in [151] where skin grafts were rejected in mice
lacking any SLOs if they harboured TLOs and generation of effector and memory T cells by TLOs was
proven. Another contribution of B cells to the immune response may be the production of cytokines
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which modulate CD4+ T cell responses. Hence, B cell clustering seems to lead to worse clinical out-
comes, although there is no direct evidence for it in the case of chronic graft rejection [201]. On the
other hand, there is evidence for regulatory function of B cells in transplantation as well, for example,
anti-CD20 treatment of naive patients enhanced acute cellular rejection and peripheral B cell numbers
were increased in patients with long-term graft functioning [42, 162, 201]. Most of the results show
a correlation between outcome and B cell presence, and must be treated carefully since the real con-
founding factor of graft failure or adaptation could be different. Probably B cell presence may be either
beneficial or negative depending on additional conditions.
Stability of immune cell clusters formation is an interesting topic which may have clinical implica-
tions. Since cell movement and differentiation is governed by molecule interaction, disturbance of this
interaction may lead to cluster resolution. For example, knocking out the CXCR5 gene in a mouse model
of rheumatoid arthritis reduced joint damage [221] and neutralizing CXCL13 with antibodies results in
TLO desorganisation in NOD mice [87]. Here, I attempt to model chemokine gradient generation and
its sensing by lymphocytes and to investigate how model parameters influence CXCL13 gradient and
lymphocyte sensitivity to it.
In order to describe such a complex system, I used an agent-based approach, i.e. every cell is treated
as an individual instance moving in space and changing its behaviour according to pre-set rules. To
efficiently track cell collisions, I implemented a collision detector algorithm, reviewed in section 3.2.1.
Since the number of secreted molecules in the system is very large, molecular interactions are easier
to model using a diffusion equation than via agent-based modelling. Having bound to a receptor, the
chemokine-receptor complex can be internalized and I included such dynamics in the model as well in
order to see what impact on the system state complex internalisation may have.
As reviewed earlier, the precise mechanisms of TLO formation are still unknown and I use simplified
assumptions about the biology of the system. I assume that B cells enter the tissue via blood vessels
and perform persistent random movement in the absence of chemokine gradients. In [111], it was
hypothesized that B cells may be responsible for stroma activation since they can provide signalling
via lymphotoxin receptor. This assumption is implemented in the model in the form of a phenomeno-
logically described signal which is integrated by stromal cells upon every contact with B lymphocyte.
Having reached a certain threshold, stromal cell start to secrete CXCL13. B cells which are able to sense
the gradient move towards the chemokine source. Simulation in different parameters ranges will show
how relevant each parameter is for the cluster stabilisation and in which condition cluster formation is
more likely.
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3.2 Framework for TLO modelling
3.2.1 Collision detection
Agent-based modelling includes the simulation of physical interaction between cells, which demands
efficient tracking of cell collisions. Collision detection is one of fundamental problems in computer
science, robotics, game development, physical simulations and computer animation. Collision detection
can be utilized for prognosis of future interactions, for example, for obstacle avoidance in robotics or
ray-tracing in animation, or it can be used for identifying already happened collisions in a system,
e.g. finding all neighbouring molecules inside the interaction radius. Depending on the system type and
the application purpose, the following two variations of collision detection algorithms are used:
Continuous collision detection aims to identify collisions a priori by modelling paths of agents and
finding their intersections in advance, before trajectories of the agents are updated. It allows to compute
the exact time of contacts, but in case of complex physics of the problem it will result in computationally
expensive calculations.
Discrete collision detection identifies contact events a posteriori, i.e. after volumes of the objects
have penetrated each other. This method is much simpler in implementation and in computational
effort but does not provide exact time points of collisions.
The choice of the algorithm depends on the size of the time step used for simulation and on the
speed of object movement. If the objects are moving very fast, an a posteriori algorithm may miss the
collision event, because in this case the objects may never overlap in the simulation due to large time
steps, when the object displacement is larger than the object size. The drawback of a priori algorithms
is their dependence on the physics of the problem and higher dimensionality of the computational
problem because one needs to consider the time component in order to predict future collisions. Since
the aim of the developed framework does not include detailed mechanistic implementation and exact
solution of physics underlying cell contacts, I decided to use an a posteriori algorithm to gain benefits of
computational performance. In the simulations, cell positions were updated with the time step of 0.1
min. For a cell speed of 10 µm/min and cell size of ≈ 10 µm, cell penetration will not exceed 2 µm, or
20% of its diameter, in the worst case.
Overview of a posteriori collision detection algorithms
The form of the objects may be very complex. In order to reduce computational costs, the first step for
a collision detection is to exclude objects pairs which do not overlap. This step is called broad-phase
collision detection. After this step, during the narrow phase, the rest of the objects are tested for exact
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Figure 3.1: Methods of object geometry representation for broad-phase collision de-
tection: (a) axis-aligned bounding box; (b) oriented bounding box; (c) bounding circle;
(d)k-discrete oriented polytope (k = 8).
collisions with respect to their geometry. In the simulations, I assume cells to be of spherical form,
hence the exact test for collision will be straightforward as
Collision status(r1, r2) =
colliding, if
‖~r1−~r2‖
‖r1‖+‖r2‖ < 1
not colliding, otherwise,
(3.1)
where ~r1, ~r2 are the radius vectors of two cells being checked for collision and ‖·‖ is the euclidean norm.
To simplify detection of object pairs during the broad phase of the algorithm, different abstractions
of the object geometry are used. The simplest representation is axis-aligned bounding boxes (AABB),
which consist of a minimal cuboid constructed for the object. There is a variety of other methods
including bounding spheres, polytopes and oriented bounding boxes, but because of the spherical form
of the cells assumed in the model, the AABB method was used for broad-phase collision detection.
The simplest way of collision candidate detection is the naive approach checking all possible object
pairs, hence it has complexity of O(n2), where n is the object number. However, there are more efficient
algorithms, which are shortly reviewed below.
Spatial partitioning algorithms. One approach to reduce the number of collision tests is to divide
the simulation space into distinct volumes and to assume that all objects located inside of the same
volume are candidates for collision and they will be investigated during the narrow phase of collision
detection later. At every simulation time step the partitioning structure is to be reconstructed as in case
of kd-trees [24] and octrees [17] or objects are sorted among grid cells if regular grids [230] or hash
tables [145] are used. The advantage of spatial partitioning is its very simple parallelization, since the
problem is divided into a high number of similar subproblems. One can choose a very small cell size. In
this case, in every cell can be at most only one object and neighbour check is very simple. On the other
hand, there exists an optimal cell size, since the number of subproblems increases quadratically with the
decrease of cell side length. Hence, it is obvious that the partitioning algorithm may lack performance
if the objects are very diverse in size.
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Figure 3.2: Overview of a posteriori collision detection algorithms.
If the number of dimensions is d then the number of neighbouring cells is 3d− 1. Having a grid with
m cells per every dimension, the average object number per cell will be nc = n/md and the number of
distances to check is [149]
p =
(
(3d − 1)nc
2
+
nc(nc − 1)
2
)
md, (3.2)
where we assume that every pair is checked only once, hence only half of the neighbouring cells is
considered every time.
Verlet lists. A similar approach is to define a cut-off distance for particles to be called neighbours and
to construct a list of this neighbourhood which is called the Verlet list [212]. In this case, the cut-off
distance Rcut is chosen in such a way that one can use the same list for nstep simulation steps, i.e.
Rcut = Rinter + nstepd, (3.3)
where Rinter is the interaction distance between particles and d is the maximum displacement of the
objects during one simulation step. In our case, Rinter is the sum of cell radia. For N objects, the
complexity of list construction isO(N2). The collision test for every simulation steps will costO(Nn2step).
This means that the value of n may be optimised to increase performance.
Triangulation An elegant approach is the construction of a Delaunay triangulation graph of neigh-
bours. In agent-based simulations, system states at two subsequent time steps are very much alike,
because cells do not move for long distances during one time step. This feature is called temporal coher-
ence of the states. The dynamic triangulation algorithm exploits this feature, because it uses previous
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Figure 3.3: Update of boundary list. ’b’ denotes for the projection beginning and ’e’
denotes for the ending respectively.
states for new graph construction which improves efficiency of collision detection [186]. In addition, a
Voronoi tessellation, the dual set of points for the Delaunay triangulation, allows to estimate cell contact
surfaces.
However, this algorithm is very sensitive to rounding errors and demands the implementation of
high-precision computations.
Sweep-and-prune algorithm. The specificity of our model system is its inhomogeneity, since cells
may form clusters. In case of the partitioning algorithms, in some grid cells there will be many objects
but some will be almost empty. This will reduce efficiency of the algorithm because its main idea is
to distribute the problem among several subproblems. The sweep-and-prune algorithm manipulates
with relative order of objects along the axes and is less sensitive to such objections. Also, the sweep-
and-prune algorithm allows to exploit temporal coherence, since it uses data structures generated at a
previous time step.
The basic idea of the sweep-and-prune algorithm is the projection of the object’s AABBs on one or
several axes [45]. In this case, one works with intervals corresponding to AABB edges. For detecting
the collision, only the relative position of the object to others is important, i.e. there is no need to define
any additional abstraction in space like grid or octree.
The first step of the algorithm is the construction of lists of boundaries for every axis, which are
generated based on the object’s AABBs. For the 3-dimensional case, we have 3 lists of length 2n, where
n is the object number, because for every object there is a beginning and an ending projection point. All
boundaries are sorted with respect to the coordinate and one can easily detect intersections between
object projection in this case. Objects are considered as candidates for collision if their projections are
intersecting at all three axes. The candidate pairs are tested with the narrow-phase collision detection
algorithm, since intersection of AABBs does not obligatory mean objects collision, for example, it can
take place for non-convex objects. In our case we use the rule from eq. 3.1 for the narrow-phase step.
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Variable Meaning
n total AABBs
k dimensions
m migrations (insertions + removals)
u updates (moving AABBs)
s swaps
o AABB pairs overlapping
e changes in o
Table 3.1: Definitions of variables used for estimation of the sweep-and-prune algorithm
complexity.
During simulation, the objects change their positions, hence, the collision status must be updated
accordingly. At every time step, AABBs boundaries are updated and sorted in the lists. Since time
steps are small enough, that objects do not move for a large distances, the boundary list will be almost
sorted after coordinate update. I used the insertion sorting algorithm, because it was shown to be
efficient for this kind of lists and using this time coherence between two system states allows to reduce
computational complexity from O(n log n) to O(n), where O(.) stands for the big O notation [19, 45].
During the sorting procedure, collision status is updated according to the following rules:
• If two left boundaries passed each other, the projections continue to be overlapping
• If two right boundaries passed each other, the projections continue to overlap as well
• If the left boundary and the following right boundary have exchanged, the projections do not
overlap any more at the axis and collision between these two objects should be removed
• If the right boundary and a following left boundary has exchanged, a new collision at the axis
appears; if the object’s projections overlap at all three axes, a new colliding pair is to be added.
The complexity may be further estimated if one includes into consideration migration events (insertions
and removals), the number of swaps, AABB coordinates updates, updates of collision status etc., the
total complexity of the collision detection workflow is O(uk+sk+e+mnk+o) [206]. For the definition
of the equation terms, see table 3.1. Further, following [206] one may estimate the number of swaps
depending on the object density. Let us consider two cubic environments E and E′ in k dimensions
having side lengths lE and lE′ and the same object volumetric density V . Hence
V =
nc
lkE
=
fnc
lkE′
, (3.4)
considering that there are n objects in E and fn in E′. From this, the side ratio lE′/lE = k
√
f can be
found. With the increase of the object number by a factor of f , the number of swaps is increased by
factor of f1−1/k. In this case, the swap number is estimated as s = ukn1−1/k. Finally, the complexity of
sweep and prune collision detection will be O(uk2n1−1/k +mnk + e+ o).
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a b
Figure 3.4: a: The collision matrix for a system with two cell clusters. The black space
corresponds to non-colliding pairs and white points are potential collisions. Since the ma-
trix is very sparse, only a 300x300 submatrix is plotted. b: Rendering of the system with
two clusters of B cells (blue) aggregated around stromal cells (yellow) (using the Mayavi
software [175]).
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Figure 3.5: Comparison of sweep and prune algorithm versus the naive approach in sim-
ulation of cell movement for different cell numbers. Only collision detection and cell move-
ment were simulated, i.e. no diffusion or other complex cell behaviour from the model was
used.
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The number of colliding object pairs is very low in comparison to the number of all possible pair
combinations, and the collision matrix for our system is very sparse, see fig. 3.4. The sweep-and-prune
algorithm allows us to avoid redundant collision testing, which dramatically increases the performance
of the collision detection in the framework. For comparison with the naive approach see fig. 3.5. The
simulation included only simple B cell movement without chemosensing. The size of the simulation box
was 1000µm x1000µm x1000µm and the simulating time corresponds to 100min.
3.2.2 Chemokine diffusion
Long range interaction between stroma and immune cells depends on the spatial distribution of
chemokine molecules and can be described with the diffusion equation:
c˙(x, t) = D4 c(x, t)− κ · c(x, t) + r(x, t, c(x, t)) + q(x), (3.5)
where
• t is the time,
• x is the position in the space,
• 4 stands for the Laplace operator, 4c = ∂2c∂x2 + ∂
2c
∂y2 +
∂2c
∂z2
• c(x, t) is the chemokine concentration,
• κ is the chemokine decay rate due to degradation,
• D is the diffusion coefficient for the chemokine,
• r(x, t) is the term describing receptor dynamics and chemokine internalization by the immune
cells. In more details, receptor dynamics is discussed in the subsection 3.2.3;
• q(x) is the secretion of the chemokine by stromal cells.
Following [218], the diffusion coefficient was estimated with the empirical formula [116, 199]
D =
A
MW1/3
= 7.3 · 103µm2/min, (3.6)
where A = 2.82 · 10−5 cm−2/s(g/mol)1/3, MW = 12664 g/mol is the molecular weight of CXCL13.
To solve the equation numerically I applied the splitting approach, which is widely used to simplify
the treatment of complex problems by sequentially solving simpler subproblems [112, 127, 193]. In
our case, the right hand side of the equation is represented as superposition of spatial term and the
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term for the chemical reaction. The numerical scheme can be split in sequential solving of the diffusion
step and reaction step:
c˙1(x, t) = D4 c1(x, t) (3.7)
c˙2(x, t) = −κ · c2(x, t) + r(x, t, c2(x, t)) + q(x) (3.8)
In this case, the equation for c1 is solved up to the next time point tn+1 using the chemokine distribution
c(x, tn) at the time step tn as the initial condition. Its solution c1(x, tn+1) is used as the initial condition
for the equation describing the reaction step c2(x, tn) = c1(x, tn+1). The chemokine distribution at the
time step tn+1 is defined as c(x, tn+1) = c2(x, tn+1).
For solving the diffusion equation I used the forward-time central-space (FTCS) explicit scheme
and the implicit Crank-Nicolson scheme. This are the so-called finite difference schemes, because the
solution is approximated by values arranged on the regular rectangular grid.
For a diffusion equation
∂c
∂t
= D
(
∂2c
∂x2
+
∂2c
∂y2
+
∂2c
∂z2
)
(3.9)
the FTCS scheme reads as
cn+1i,j,k − cni,j,k
τ
=D
cni+1,j,k − 2cni,j,k + cni−1,j,k
h2x
+ (3.10)
D
cni,j+1,k − 2cni,j,k + cni,j−1,k
h2y
+D
cni,j,k+1 − 2cni,j,k + cni,j,k−1
h2z
,
where h∗ is the discretization step in space, τ is the time step, i, j, k are the indexes of grid points for x,
y and z axis, respectively. This scheme is conditionally stable, i.e. it is stable if and only if the following
Courant condition is satisfied:
Dτ
2
(1/h2x + 1/h
2
y + 1/h
2
z) < 1. (3.11)
The FTCS scheme is very easy to implement but may demand very small time steps because of the
stability condition. That is why an implementation of the Crank-Nicolson scheme was used, which is
derived as a half-sum of forward and backward Euler method:
cn+1i,j,k − cni,j,k
τ
=
D
2
(
cni+1,j,k − 2cni,j,k + cni−1,j,k
h2x
+
cn+1i+1,j,k − 2cn+1i,j,k + cn+1i−1,j,k
h2x
+ (3.12)
cni,j+1,k − 2cni,j,k + cni,j−1,k
h2y
+
cn+1i,j+1,k − 2cn+1i,j,k + cn+1i,j−1,k
h2y
+
cni,j,k+1 − 2cni,j,k + cni,j,k−1
h2z
+
cn+1i,j,k+1 − 2cn+1i,j,k + cn+1i,j,k−1
h2z
)
.
Since this scheme is implicit, it demands solving of a system of linear algebraic equations. I used
an implementation of the biconjugate gradient method and the Crank-Nicolson scheme from [187].
The implicit scheme is unconditionally stable, it means it is numerically stable at any time and space
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discretization step sizes. Although the implicit scheme allows making large time steps, in our case it
appeared that the explicit scheme is faster at time steps in its stability region, hence throughout the
work I used only the FTCS-scheme.
For boundary conditions, I used Dirichlet conditions at x and y axis with 0 concentration. In the
simulations I consider a cylindrical blood vessel positioned in the center of the simulation box with the
size of Lx×Ly ×Lz. I assume that the vessel length is much longer than Lz and use periodic boundary
conditions along Z axis, i.e. concentration at up and down are always equal:
c|x=0 = 0, c|x=Lx = 0 (3.13)
c|y=0 = 0, c|y=Ly = 0 (3.14)
c|z=0 = c|z=Lz . (3.15)
The reaction rate v of the proteolytic degradation can be described with Michaelis-Menten kinetics
v =
kcatcE
Km + c
, (3.16)
where E is enzyme concentration, kcat is the catalytic rate constant, Km is the Michaelis constant.
Assuming chemokine concentration to be small, the reaction rate can be simplified to
v =
kcatcE
Km
= κc. (3.17)
The degradation rate of CXCL13 in tissue is not known but there are available data about proteolysis
of other chemokines. In [37, 218] where chemokine gradients were modelled, degradation kinetics
were based on the analysis of [23, 113, 170, 205, 229], and κ was estimated to be in the range of
10−5 − 5 · 10−3s−1. Given eq. 3.17, the degradation step during the simulation is described with the
exact solution of first-order kinetics
cn+1 = c
∗
n+1e
−κτ , (3.18)
where c∗n+1 is the concentration calculated after diffusion step and κ is the degradation rate.
Chemokine secretion is modelled as a point source at the closest grid point in respect to the stromal
cell
q(xi, yj, zk) =
q
V
, (3.19)
where V = hxhyhz is the volume of a grid cell, i, j and k are the X, Y and Z axis indexes of the grid
point and q is the secretion rate by a single cell.
The secretion rates of other chemokines were used as estimation for q in the simulations. In [218],
the CXCL12 secretion rate range was estimated as 0.01-1 pg/hr/cell (or 8 · 103−5 molecules/cell/min)
based on [41, 94, 117, 185]. Also a measurement of CXCl13 secretion rate by macrophages was re-
ported in [32], where primed cells were able to secrete the chemokine at rate of 11 molecule/min.
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Figure 3.6: A scheme of receptor dynamics. Chemokine forms a complex with a receptor
which is internalised by the cell. The free receptor is recycled to the cell surface.
In experiments with microfluidic device for the generation of CXCL12 gradient, the transduced breast
cancer cells were secreting the chemokine at rate of 15-25 molecules/cell/s (900-1500 molecules/cel-
l/min) [36] and this range was used later in computational modelling of the gradients in a similar
set-up in [37]. Based on these estimations, the CXCL13 secretion rate is assumed to be in the range
103 − 105molecules/cell/min.
3.2.3 Receptor dynamics
Chemokines are sensed by cells via receptors at their surface. Upon binding, ligand-receptor pairs are
being internalised by the cell and the receptor is recycled back to the surface later. I do not include
phosphorylation of the receptor [119] into the model or, for example, its interactions with β-arrestin
[37] and describe the kinetics of chemokine-receptor complexes phenomenologically without underly-
ing mechanism implementation, fig. 3.6.
The internalisation process changes the chemokine concentration at the lymphocyte location. The
receptor dynamics can be described by the system of ordinary differential equations which has to be
coupled with the chemokine dynamics:
R˙ = −konRc+ koffRb + krRi (3.20)
R˙b = konRc− koffRb − kiRb (3.21)
R˙i = kiRb − krRi (3.22)
c˙ = −konRc+ koffRb, (3.23)
where
• kon and koff are rates of binding and unbinding of chemokine to receptors,
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• ki is rate of receptor-chemokine complex internalization,
• kr is rate of receptor recycling to the cell surface;
• R is the number of free surface receptors,
• c is the concentration of the chemokine,
• Rb is the number of receptor-chemokine complexes (bound receptors),
• Ri is the number of internalized receptors.
Instead of absolute receptor numbers, I use concentrations calculated as receptor number divided by
the grid cell volume V , in order to comply with dimensions in the kinetic equation. The total number
of receptors is assumed to be constant within the simulation time: Rtotal = R + Rb + Ri. Hence, the
system can be simplified to
R˙ = −konRc+ koff(Rtotal −R−Ri) + krRi (3.24)
R˙i = ki(Rtotal −R−Ri)− krRi (3.25)
c˙ = −konRc+ koff(Rtotal −R−Ri). (3.26)
To solve these equations I used an implicit Euler scheme, because it is stable and can be used for stiff
systems where the processes have different kinetic rates [30]. In our case, the system is stiff due to a fast
binding of chemokine to receptors and a slower reaction of receptor internalization. In case of a single B
cell, the implicit scheme may be treated analytically and it was decided to follow the splitting technique
as mentioned above and to solve the receptor dynamics equations sequentially for cells located at the
same grid point. The implicit Euler scheme yields the system
Rn+1 −Rn
τ
= −konRn+1c+ koff(Rtotal −Rn+1 −Ri,n+1) + krRi,n+1 (3.27)
Ri,n+1 −Ri,n
τ
= ki(Rtotal −Rn+1 −Ri,n+1)− krRi,n+1 (3.28)
cn+1 − cn
τ
= −konRn+1cn+1 + koff(Rtotal −Rn+1 −Ri,n+1) (3.29)
with the exact solution
Rn+1 =
−B +√B2 − 4AC)
2A
(3.30)
Ri,n+1 = α2 − α3Rn+1 (3.31)
cn+1 = (Rn+1 − τkrRi,n+1) + α1, (3.32)
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where
α1 = (cn −Rn), α2 = Ri,n + τkiRtotal
1 + τ(ki + kr)
, α3 =
τki
1 + τ(ki + kr)
(3.33)
A = konτ(1 + α3τkr) (3.34)
B = 1 + τkoff + α3τ(kr − koff) + konτ(α1 − τkrα2) (3.35)
C = −τkoffRtotal − τ(kr − koff)α2 −R0 (3.36)
For the parameters values in the model, I use estimations for similar receptors in experiments with T
cells and cancer cell lines. The only available parameter values for the CXCL13-CXCR5 pair are kon and
koff rates which were are measured in [21], kon = 7.7 · 104 M−1s−1 and koff = 3.5 · 10−3s−1. For CXCR5,
there are no available data about internalization and recycling dynamics, and data for CXCR4 are used
as an estimation instead [36, 44]. The internalization rate is ki = 4.7 · 10−3s−1 and the recycling rate is
kr = 6.9 · 10−5s−1.
The density of CCR7 receptors in T cells is estimated as 2 · 104 receptors/cell [224]. In case of trans-
fected cancer cell lines in [37] the density of CXCR4 is 7.1 ·105 and for CXCR7 it is 2 ·106 receptors/cell.
The same work refers to a previously measured receptor density interval for cancer cells as 103 − 105
[89, 156]. Based on these results, we will perform simulations assuming the receptor number to be in
the range of 103 − 106 per cell.
3.2.4 Cell migration
Cell movement is governed by a signal which they get from the chemokine receptors. Chemokines are
secreted in order to position cells within certain regions. As discussed in sec. 2.2, secretion of CXCL13
by stromal cells, which are differentiated into FDCs, attracts CXCR5+ B lymphocytes.
Directed migration of cells depends on their ability to get polarized along with the direction of
chemokine concentration gradient. I assume that a B cell defines its direction based on the difference
of receptor-chemokine complexes at two opposing sides [119]. Since the receptor binding is the fastest
process in the system, we may consider the reaction in equilibrium, i.e.
koncR = koffRb. (3.37)
Assume that the total surface receptor numbers at opposite cell sides are equal R− + R−b = R
+ +
R+b = Rsurface/2, where R
+ + R− = R, R+b + R
−
b = Rb. For a small concentration difference 4c, the
difference in bound receptors is estimated as
4Rb = Rsurface 4 c
2(Kd + c)
, (3.38)
where Kd is the dissociation constant for the chemokine, 4c = |∇c|d is the difference in chemokine
concentration at the opposite cell sides, d is the diameter of the cell, ∇c stands for the chemokine
34
100
200
300
1e−10 1e−09 1e−08
c, nM
∆R
b
Figure 3.7: Difference in bound receptor numbers depending on concentration according
to the eq. 3.38. The chemokine concentration difference 4c is set to be constant.
gradient. The difference in bound receptors depends not only on the steepness of the gradient but on
the absolute chemokine concentration as well. An example of such a dependency is shown at fig. 3.7.
A cell performs persistent random walk if the difference 4Rb is too low and it moves along with the
chemokine gradient otherwise. I use the threshold number 4Rb > 10 which is justified by estimation
of fluctuations in bound receptors [207] and is used in [119, 218] for modelling of cell polarization in
the presence of the chemokine gradient.
According to [143], a B cell has a persistence time tpersist = 1.24 min, after which it changes its
direction according to the chemokine field. I use the speed value estimated from two-photon imaging
of B lymphocytes vB = 6.4 µm/min [143], if not otherwise specified.
The detailed modelling of physical interactions is beyond the scope of this work. If two cells collide,
their interaction is simplified with an elastic repulsion force
F = max(F0, k‖~r1 − ~r2‖) · ~r1 − ~r2‖~r1 − ~r2‖ , (3.39)
where F0 is the maximal force magnitude, which is introduced in order to prevent high speed jumps of
the cells. I neglect cell acceleration in computation of cell movement, assuming that the viscosity of the
medium in the tissue is high enough, and cell speed is constant during a time step. Hence, cell velocity
can be found from Stock’s law
~v = ~F/γ (3.40)
To put aside detailed physics of cell contacts, we may use arbitrary force units which can be mapped
to cell velocity then. In this case γ = 1µm/(min · a.u.) and k = 10 a.u./µum, where a.u. stands for
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arbitrary units. Active cell migration of B lymphocytes is implemented as
~F = γvB~p, (3.41)
where ~p is the direction of B cell polarization. Inside the blood vessel cells are subjected to an additional
force which pushes them away from the vessel in the X-Y plane (the vessel is directed along the Z axis):
Fvessel = 1a.u. · ~r − (r, ez)ez‖~r − (r, ez)ez‖ (3.42)
3.2.5 Stromal cell activation
Stromal cells change their phenotype due to interaction with B cells, which migrate inside the tissue.
In our model, stromal cell are represented as static spheres, which are distributed with the constant
density in the simulation space. There are no available data about the stromal cell size in the condition
of chronic inflammation. Being differentiated into FDCs, they may have a complex morphology charac-
terised by dendrites with the length of 15-20µm [196]. Without loss of generality, I assume that stromal
cell have a diameter of dstroma = 15µm. This parameter can be adjusted in the future if the data about
stroma morphology are available.
I assume that the structure of the stroma environment is not tight due to edema [49], a process
of accumulation of liquid during chronic inflammation. As with the stromal cell diameter, the density
of this cells is not known as well. Stromal cells are positioned with density which corresponds to
rectangular packing of cells with the interval of 2dstroma, i.e.
dstroma =
1
(30µm)3
= 3.7 · 10−5µm−3 (3.43)
If a B cell gets in contact with any stromal cell, it stops moving for the interaction time tinter = 1min.
After this time period, the B cell reverts its direction and continues migration.
Since there is no known mechanism of stroma activation, I implemented a phenomenological model
based on the signal integration model for T cell activation [173]. I define the signal as cumulative time
of interaction and after every contact, the value increases with tinter. A cell has a limited memory for a
contact, and contribution of every interaction decays exponentially with time. If the signal achieves the
threshold value θ, the stromal cell is assumed to differentiate into an FDC phenotype and it starts to
secrete CXCL13. This process is supposed to a have a limited memory, i.e. cell contacts which happen
long time ago do not contribute to stromal cell fate decision. I illustrate this kind of process in the next
section where I introduce the decay rate d, which is an arbitrary value, as well as the signal threshold.
3.2.6 Implementation
There is a big variety of paradigms for computer program development. The object-oriented ap-
proach is one of the most popular for agent-based simulations. It can be explained by the sim-
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plicity of translation of the model into programming language code, since the main term is the
object itself. For example, in our case, to describe B cells we would need to introduce a class
s t ruc t BCel l {
s i z e _ t id ;
const double rad ius ;
const double maxSpeed ;
const double r e cep to rTo ta l ;
double nextTurningTime ;
Vector d i r e c t i o n ;
Vector p o s i t i o n ;
Vector v e l o c i t y ;
double r ecep to r ;
double i n t e rna l i z edRecep to r ;
} ;
Listing 3.1: OOP B cell class
Every object of this class has information about cell position, direction, velocity etc. Although it is
much easier to map the model to the code, this approach has its drawback in cache utilization. For
example, if we have a vector of B cell objects and we would like to update coordinates of the cells, there
will be a lot of cache misses due to data layout in memory, since data from one object in this case will
be packed together.
An alternative approach for the code design is so-called data-oriented programming [125]. The
main idea of it is to abstract from objects to data and to consider the program as processing of a
data flow. The agents are divided in simpler components which can be processed with small func-
tions using less data. In this case, instead of vector of structures we deal with structure of vectors:
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s t ruc t BCe l l s {
Movables * movables ;
Co l l idab leSphere s * c o l l i d a b l e s ;
const double rad ius ;
const double maxSpeed ;
const double r e cep to rTo ta l ;
s td : : vector<s i z e _ t > IDs ;
s td : : vector<double> nextTurningTime ;
s td : : vector<Vector> d i r e c t i o n s ;
s td : : vector<double> recep to r ;
s td : : vector<double> in te rna l i z edRecep to r ;
} ;
s t ruc t Co l l idab leSphere s {
s td : : vector<s i z e _ t > IDs ;
s td : : vector<Cel lTypes> ce l lType s ;
s td : : vector<Vector> p o s i t i o n s ;
s td : : vector<double> rad ius ;
} ;
Listing 3.2: DOD B cell class
The class of B cells is linked to components for collidable objects and for movable objects and it dele-
gates storing of information about position and velocity to these two classes and includes only B cell
specific data. If one needs to update the position of all cells given their velocities, it can be done by
a very simple function which takes a vector of velocities and cell positions, allowing for more efficient
cache-utilization, since all position data are closely packed now. This approach is structurally very sim-
ilar to relational databases, because structures of vectors can be seen as data tables now with unique id
keys to connect information of the same B cell. Another useful advantage of this approach is that the
set of functions performing actions on vectors are simple to parallelize.
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Symbol Meaning Value Range∗ Units Reference
q CXCL13 secretion rate varying 10− 105 molecules/(cell ·min) [32, 36, 37, 41, 94,
117, 185, 218]
Rtot surface receptor number varying 103 − 106 # [37, 89, 156, 224]
κ CXCL13 degradation rate 10−5 10−5 − 10−3 s−1 [18, 23, 113, 170,
205, 218, 229]
vB B cell speed exp 6.4-8.3 µm/min [43, 143]
tpersist persistence time for B cell exp 1.24 min [143]
rB B cell radius exp 5.5 µm [71]
dS stromal cell density assum 3.6 · 10−5 µm−3
rS stromal cell radius assum 7.5 µm
tinter interaction time assum 1 min
θ activation threshold varying 10-20
d signal decay varying 0.01-0.05 min−1
4Rb threshold of bound recep-
tor difference
estimated 10 # [119, 207, 218]
kon receptor-CXCL13 binding
rate
exp 7.7 · 104 M−1s−1 [21]
koff receptor-CXCL13 dissocia-
tion rate
exp 3.5 · 10−3 s−1 [21]
Kd dissociation constant exp 5.05 · 10−8 M [21]
ki internalization rate exp 4.7 · 10−3 s−1 [44]
kr receptor recycling rate exp 6.9 · 10−5 s−1 [44]
rV vessel radius assum 60 µm ca. 10 cells
Table 3.2: Model parameters.
3.3 Simulations
3.3.1 Stochastic modelling of signal integration for a single stromal cell
According to our assumptions, interactions between B cells and stromal cells play the key role in ac-
tivation of stromal cells. We expect that rare contacts are not able to induce stroma differentiation,
otherwise any contact with lymphocytes would result in TLO development and these structures would
be observed ubiquitously in a healthy organism. Frequency of contacts is directly related to B cell
concentration, which is a measurable value. Moreover, immunosuppresive therapy with Rituximab is
directed exactly to control the B cell numbers. To investigate how stroma activation could depend on
the B cell number, I constructed a simplistic stochastic model of signal integration. A similar proposition
was made for T cell activation via temporal signal integration [173]. In this model, I consider a stromal
cell which is located in a volume filled with randomly moving B cells. Due to random collisions, a
stromal cell will get in a contact with B cells and get an activation signal α. I consider here that stroma
cells have limited memory, i.e. signal decay is modelled as
S˙ = b(t)− dS, (3.44)
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where d is a decay parameter and b(t) is the signal from a B cell. For simplicity, I assume that after every
interaction S increases as α, and for given interaction times τ1, τ2 . . . τn the equation reads
S˙ = α
n∑
i=1
δ(t− τi)− dS, (3.45)
where δ(t) is the Dirac delta function. Having zero signal in the beginning, the solution is
S(t) =
(
α
n∑
i=1
[t ≥ τi]edτi
)
e−dt, (3.46)
where the indicator function is defined as
[t ≥ τ ] =
1, t ≥ τ0, t < τ (3.47)
It is straightforward to treat equation 3.44 if the times of interaction are given, but in reality b(t)
is a Poisson random process and the equation 3.44 becomes a stochastic-differential equation. To
describe our system evolution in time, I perform numerical simulations, see fig. 3.8. The contact times
are generated from a Poisson distribution by algorithm 3.1, p. 41, and the signal S can be computed
according to eq. 3.46 for the period of time [0, T ]. Since in the model, a stromal cell gets activated
when a certain threshold value of a signal θ is achieved, it is interesting to characterise the expected
time of activation and at which frequency of contacts the signal will be above the threshold for most of
the time. Hence, I defined two measures of interest here:
• first passage time, the time needed to reach the threshold value θ starting from zero signal S(0) =
0
Figure 3.8: Example of stromal cell signal simulation for the frequency of 1 interaction
per minute and decay rate d = 0.1min−1.
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Algorithm 3.1: Algorithm for generation of Poisson events.
/* For a given time interval [0,T] and frequency f:
generate event number */
N ←− Poisson(fT )
/* generate times of events: */
for i ∈ 1..N do
Ti ←− Uniform(0, T )
sort event times T1, T2 · · ·TN → τ1, τ2 · · · τN
Figure 3.9: Dependency of first passage time for a threshold value of θ = 10 (left) and
for varying signal decay and cell contact frequency values (right).
Figure 3.10: Dependency of signal 5% percentile for varying signal decay (left) and cell
contact frequency values (right).
• 5% percentile of the signal distribution during the time, i.e. a signal value S0.05 such that∫ T
0
[S(t) < S0.05]dt
T
= 0.05, (3.48)
where [.] is the indicator function.
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Figure 3.11: Phase diagram for stromal cell activation for a signal threshold of θ = 10.
As fig. 3.9 shows, the first passage time dramatically decreases as the frequency of contacts increases.
This means that the contact frequency is a crucial parameter of the system and that the lymphocyte
concentration in the stroma area defines the activation time. Since immunosuppresive therapy helps
to decrease lymphocyte numbers, this simulation suggests that a moderate decrease in lymphocyte
concentration may lead to a higher order increase in the expected first passage time, hence, a longer
expected time for stroma activation.
A complement measure, the 5% percentile S0.05 (see fig. 3.10) shows a linear dependency of S0.05
on the contact frequency. Unfortunately, there are no available experimental data on stroma activation,
and although this model is rather abstract, one may see that at a certain signal decay rate and contact
frequency, the signal S will be above the threshold θ for 95% of time, i.e. S0.05 > θ, see fig. 3.11.
One may associate this regime with a stable activation of stroma, which may result in development of
lymphocyte clustering due to continuous chemokine secretion.
Conclusion
• The stochastic model with decay for stromal cell signal integration illustrates that contact fre-
quency may be a very good controller for first passage time, i.e. for stroma activation.
• The system parameters, signal decay rate d and contact frequency f , define regions in which
stroma remains activated most of the time and where the signal is above the threshold (resting).
3.3.2 Contact frequency in perivascular space
In order to test our collision detection algorithm and to investigate how the position of a stromal cell
in tissue influences the contact frequency with lymphocytes, I performed simulations for a case of cell
influx from a blood vessel into the tissue. If migrating cells leave the perivascular area they are deleted
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from the simulation, if a cell reaches upper or bottom bound I apply periodic boundary conditions,
i.e. the cell appears from the opposite side. In this case, cell migration without chemotaxis is similar to
molecule diffusion, hence this problem can be compared with the solution of the diffusion equation for
a cylinder [34]:
B(r) =
(B2 −B1) log r +B1 log r2 −B2 log r1
log r2 − log r1 , (3.49)
where B1 and B2 are concentrations of lymphocytes at the inner radius r1 and at the outer one r2. In
case of zero Dirichlet boundary conditions (i.e. all cells reaching the outer boundary are deleted), the
equation is simplified to
B(r) =
B1 log(r2/r)
log(r2/r1)
. (3.50)
Since contact frequency of stromal cells with lymphocytes is proportional to the concentration of the
latter (for a given stromal cell density), the dependency of the contact frequency f(r) on the distance
from the vessel centre r will look linear in logarithmic scale for r.
I constructed a system of stromal cells surrounding a blood vessel of diameter equal to 10 lym-
phocytes sizes (as it was suggested after biopsy investigation, Prof.Dr. Friedrich Feuerhake, Medical
Hannover School, personal communication). Stromal cells were positioned at random positions with
the uniform density as described in sec. 3.2.5. Collisions between cells were tracked in the region of
600µm radius around the vessel (21141 stromal cells in total in the 1540µm x 1540µm x 490µm box).
B cell movement is subjected to periodic boundary condition along the Z-axis: if a B cell reaches the top
or bottom boundary of the simulation box, it appears at the opposite side. B cells enter the tissue from
the blood vessel with the frequency fB = 0.05 cell/min. I was interested to estimate contact frequency
in a steady state, hence after starting the simulation with a prepositioned number of B cells, I tracked
the total B cell number to see when the system is stabilized. Indeed, the frequency of contacts was
logarithmically dependent on the distance from the vessel, fig. 3.12. Perivascular cells have a higher
chance of activation in the frame of our assumptions, since according to the previous section, the first
passage time for activation may dramatically vary upon change of the contact frequency, see fig. 3.9.
Hence, cell position in the tissue might influence its phenotype because of different contacts frequency,
see fig. 3.13.
Conclusion
• I constructed framework for collision detection between cells and tested it in the condition of
constant B cell influx to the perivascular area of stromal cells. The frequency of contacts decreases
logarithmically with the distance from the blood vessel.
• The stromal cell position may influence the probability of its activation because of the decrease
in the cell contact frequency at the periphery and, consequently, the increase of the first passage
time for activation.
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Figure 3.12: Frequency of contacts between stromal cells and B cells depending on the
distance from the blood vessel. The smoothing line corresponds to the fit with LOESS
regression generated with ggplot2 package for the R statistical environment [222].
Figure 3.13: Frequency of contacts between stromal cells and B cells in single cell repre-
sentation.
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3.3.3 Chemokine gradient profile
Estimation of concentration with exact and numeric solution
Stromal cells are assumed to secrete the chemokine CXCL13, which spreads in the environment via
diffusion and can be degraded by proteolysis. Let us consider a spherical cell secreting the chemokine
with the rate q. This system has radial symmetry and the chemokine concentration c can be described
with the following diffusion equation
∂c
∂t
=
1
r2
∂
∂r
r2
∂
∂r
Dc− κc, (3.51)
where D is the diffusion coefficient for CXCL13, κc represents degradation of the chemokine and r is
the distance from the cell position. For simplicity, I assume zero boundary condition at infinity and a
constant secretion rate at the cell surface:
c|r→∞ = 0 (3.52)
4piρ2D
∂c
∂r
|r=ρ = −q (3.53)
where ρ is the cell radius. Here we are interested in a steady-state solution, namely
c = const → ∂c
∂t
= 0 (3.54)
1
r2
∂
∂r
r2
∂
∂r
Dc− κc = 0 (3.55)
By substitution v = rc the eq. 3.55 is reduced to
∂2v
∂r2
=
κ
D
v (3.56)
with the solution
v = C1e
√
κ/Dr + C2e
−
√
κ/Dr. (3.57)
C1 = 0 from the boundary condition of c = 0 at infinity, hence, from eq. 3.53 we get
c(r) =
q exp
(−√ κD r)
4piDr
(√
κ
Dρ+ 1
)
exp
(−√ κDρ) . (3.58)
This analytical solution describes the concentration of CXCL13 if the environment size would be infinite.
In reality and in our simulations, the system size is limited to the organ size or simulation box, respec-
tively. Since the analytical solution is rather easy to treat, I will use it in order to estimate chemokine
profiles for different system parameters. It is interesting to compare the numerical solution with the
exact one at the order of distances of the simulation box size. The solutions are very close to each other
in the vicinity of the cell and the difference between them does not exceed 2 · 10−13M, fig. 3.14.
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Figure 3.14: Comparison of the exact solution for CXCL13 distribution depending on the
distance from the secreting cell in infinite space with the numerical solution for a finite
simulation box with zero boundary condition (top); the difference of the exact and the
numerical solutions in comparison to the numerical solution (bottom).
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The accuracy of the numeric solution can be estimated by direct comparison of solutions made
with different step size. For a fixed simulation box size (1540µm), I performed a simulation with 50
secreting cells (Q = 104 molecules/min) which were positioned as a cluster with such density that the
average distance between neighbouring cells was equal to the cell size. I used a lattice with 45 or 89
grid points (equivalent to 44 and 88 grid cells, with 35µm or 17.5µm cell size respectively). For the
chemokine concentration, the relative error is of 1% order (fig. 3.15, the left panel). Since cells measure
not the absolute concentration when they navigate in the model but the concentration gradient, I was
interested to see how the step size influences estimation of the gradient, namely, the difference of the
bound receptor 4Rb (eq. 3.38), as this is the value used for cell orientation in the simulations. For
the estimations of the error in 4Rb, the same total receptor number Rtot = 105 as in our agent-based
simulations is used.
The step size indeed influences the estimation of 4Rb, and the error in 4Rb reaches the value of
8 in the vicinity of the cluster centre, see fig. 3.15, the right panel. Outside the cluster, the difference
is much lower than the threshold of sensitivity 4Rb = 10, hence the migration of cells which are not
trapped into the cluster does not depend on the lattice cell size. This effect is observed because a
rectangular grid is used for estimation of the chemokine distribution and its gradient, however, stromal
cells are positioned not exactly at the lattice points but at an arbitrary space location. Since secretion
is assumed to happen at the closest grid point, a change in grid step size may result into a shift of the
approximated location of the chemokine source. Usage of finite element methods with an adaptive grid
or a construction of more dense grid in our approach could increase the accuracy, however, at the price
of losing of computational speed.
System size effect can be investigated in a similar way as it was done with the lattice cell size. I
performed a simulation for the same cluster of 50 secreting stromal cells using simulation boxes with
44 or 88 (a box of double size) lattice cells with 35µm step. The difference in concentration was less
than 10−13M−1 within a radius of 500µm around the cluster, i.e. the region where its level is detectable
for cells, see fig. 3.16, left side. The receptor difference was less than 1 along the whole simulation box
space (fig. 3.16, right side) and we may conclude that for clusters near the centre of simulation box the
box size does not influence the orientation of the cells.
Conclusion
• The approximation of the chemokine distribution around a secreting cell with the analytical solu-
tion for an infinite space and the numerical solution for a finite size simulation box are comparable
at the distances of characteristic cluster sizes.
• The step size used in the simulations achieves 1% accuracy for chemokine concentration. The
calculation of gradients estimation is influenced by the lattice step size, but outside the cluster it
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Figure 3.15: Grid cell size effects. CXCL13 concentration and 4Rb were compared for
45× 45× 45 and 89× 89× 89 grids.
is less than the sensitivity threshold of 10 receptors (for cluster of 50 stromal cells). Hence, the
description of lymphocyte trapping is not strongly influenced by the step size
• The difference of receptor at opposite cell sides is not influenced (< 0.1) by the simulation box
size in the whole simulation box space.
Chemokine field for a single secreting cell
It is interesting to investigate how the chemokine is distributed around a single secreting cell. I varied
the secretion rate Q and the degradation rate κ and found out that the degradation of chemokine does
not influence the CXCL13 profile much while being in the range of 10−5 − 10−3s−1, fig. 3.17. The
receptor difference at the opposite cell sides 4Rb depends on the total surface receptor number Rtotal
and on the secretion rate Q of CXCL13, and for Rtotal = 105 it achieves the threshold value 4Rb > 10
only in the vicinity of the cell and if the secretion rate Q > 104 molecules/min, fig. 3.17, right-up.
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Figure 3.16: System size effects. CXCL13 concentration and4Rb for a single and double
size of the simulation box.
I calculated 4R for a range of secretion rate Q and total receptor numbers Rtotal and estimated the
maximal trapping distances by a single secreting cell, fig. 3.18. This result suggests that the cluster
stability can be disturbed via the decrease of available receptors number or of the chemokine concen-
tration. Measurement of q and Rtotal for human cells will help to estimate treatment concentrations for
chemokine or receptor blocking molecules.
Next, I tested at which value of the degradation rate the chemokine concentration can be pro-
nouncedly disturbed in the vicinity of the single secreting cell, fig. 3.19. The calculation suggests that
the degradation of the chemokine may contribute to change of its concentration at distances longer than
50µm and at the upper limit of the value range of κ, i.e. when the chemokine lifetime is of order of
minutes. In this case, one needs to increase the proteolytic degradation rate by 1-3 orders of magnitude
in order to noticeably change chemokine concentration in the vicinity of a single secreting cell.
Conclusion
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Figure 3.17: The concentration of CXCL13 and the estimated receptor difference at op-
posite cell sides for Rtot = 105 for a single stromal cell secreting the chemokine in infinite
space.
Figure 3.18: Maximal trapping distance by a single secreting cell depending on the se-
cretion rate q and total receptor number Rtotal at the lymphocyte surface.
50
Figure 3.19: Decrease of chemokine concentration depending on the chemokine degra-
dation rate κ. White lines stand for the assumed literature range for κ.
• A single secreting cell is able to generate chemokine gradients which can be sensed by lymphocytes
only in a certain range of secretion rates and surface receptor differences.
• Both, chemokine molecules and receptors, are good targets for treatment strategies aiming to
destabilize clustering of immune cells.
• The degradation rate does not influence the chemokine profile at the distances of 50µm and one
needs to increase amounts of proteolytic enzymes by 1-3 orders of magnitude in order to observe
substantial chemokine concentration changes in the vicinity of a single cell.
Contribution of chemokine consumption
Receptor dynamics at the cell surface may influence the chemokine distribution, because bound recep-
tors are subject to internalization with further chemokine degradation inside the cell. It is interesting
to estimate how the chemokine field will be disturbed by this phenomenon. First, consider a point
source of CXCL13 surrounded by B cells with the density nB. I will use nB which corresponds to rect-
angular packing of lymphocytes with the distance of 10µm between centres. Using the same boundary
conditions as in the previous section, the chemokine distribution c(x, t) can be described
∂c(x, t)
∂t
= D4 c(x, t)− κc(x, t)− konr(x, t)c(x, t) + koffrb(x, t), (3.59)
where r(x, t) and rb(x, t) are distributions of free and bound receptors in the space.
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We would like to estimate how much chemokine consumption might influence the chemokine pro-
file. For this, I approximate the chemokine and receptor distributions c(x, t) and r(x, t), which depend
on discrete lymphocyte positioning, by averaging receptor densities in space according to the lympho-
cyte density nB. It allows to treat this problem analytically, which helps to simplify the analysis.
In a steady state, for a single cell and chemokine concentration c at its location
R˙ = −konRc+ koffRb + krRi = 0 (3.60)
R˙b = konRc− koffRb − kiRb = 0 (3.61)
R˙i = kiRb − krRi = 0 (3.62)
The total receptor number is Rtot = R+Rb +Ri, hence the number of bound receptors for a single cell
can be represented as a function of the chemokine concentration:
Rb =
Rtotc
ki + koff
kon
+ c
(
1 +
ki
kr
) (3.63)
Using the values for the kinetic rates one gets
Rb =
Rtotc
10−7M + 69c
(3.64)
This equation can be approximated with the linear relation
Rb =
konRtotc
koff + ki
= 107M−1 ·Rtotc (3.65)
for chemokine concentrations c < 10−9M , which is true for the case of a single secreting cell, for
example.
We can substitute terms for binding and unbinding kinetics in the diffusion equation using eq. 3.61
konRc− koffRb = kiRb and by combining receptor numbers for a single cell and cell density nB:
D4 c− κc− ki konRtotnBc
koff + ki
= 0 (3.66)
The last two terms of the eq. 3.66 can be grouped as (κ + ki konRtotnBkoff+ki )c = κ
∗c, which leads to the
same form of equation as eq.3.55, only with the modified degradation rate κ∗. The solution reads
c(r) =
q exp
(
−
√
κ∗
D r
)
4piDr
(√
κ∗
D ρ+ 1
)
exp
(
−
√
κ∗
D ρ
) . (3.67)
In fig. 3.20, one can see that for high receptor numbers (105 − 106), receptor internalisation indeed
may decrease the amount of chemokine. However, there are two competing phenomena here: on the
one hand, high receptor numbers at the cell surface will result in higher chemokine consumption and
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Figure 3.20: CXCL13 distribution in the case of a single secreting cell surrounded by a
space filled with densely packed lymphocytes in absolute concentration values (left) and
as a fraction with respect to the case of no consumption (right). The estimations are made
for the secretion rate q = 105 min−1 and varying total receptor number Rtot.
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Figure 3.21: Left: Concentration decay due to receptor internalisation depending on the
total receptor number Rtot. Right: Bound receptor difference at the opposite cell sides as
a function of the total receptor number Rtot. The estimations are made for the secretion
rate q = 105min−1 and for the distance from the secreting cell r = 50µm.
53
Figure 3.22: Left: Regions in the space where the bound receptor difference is higher
than the threshold 4Rb > 10 (i.e. cell will be trapped by chemokine gradient) depending
on the total number of surface receptors. The secretion rate is q = 105min−1. Right: The
optimal value of the total receptor number R˜tot computed for different degradation κ and
secretion q rates.
Figure 3.23: Left: R˜tot as a function of kon. Right: R˜tot as a function of koff. Red triangles
correspond to estimations for kon and koff used in the model.
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might destabilize clustering. On the other hand, higher receptor numbers allow better sensitivity, since
the critical threshold4Rb > 10 can be achieved easier. In steady state4Rb is estimated using eq. 3.65
4Rb = konRtot 4 c
2(koff + ki)
, (3.68)
where 4c is the difference in CXCL13 concentration at opposite cell sides. It appears that for given
kinetic parameters there is a peak for bound receptor differences at around 106 receptors/cell (however,
it should be less for higher affinity receptors) and at higher receptor numbers, chemokine consumption
does not allow chemosensing, fig. 3.21.
For this model, one may define regions in the parameter space where a cell can be or can not
be trapped by the gradient. The phase diagram for the receptor number and the distance from the
chemokine secreting source shows the maximum trapping distance for different receptor numbers,
fig. 3.22, left. There exists an optimal receptor number R˜tot in terms of maximal trapping distance,
i.e. maximal cluster radius. This value depends on the strength q of the chemokine source, but the
degradation rate κ does not influence much R˜tot, fig. 3.22, right. However, in the case of a single
secreting cell, R˜tot is of very high values (106 − 107 receptors), which are out of the assumed range for
Rtot for lymphocytes (104 − 105 receptors). A lower R˜tot might be observed for more affine receptor-
chemokine pairs, i.e. for higher kon or lower koff values, fig. 3.23. I solved the boundary problem
numerically using the R package bvpSolve [136], because the linear approximation from eq. 3.65 may
deviate from the exact solution for higher affinities.
Conclusion:
• In the model of a point chemokine source in the space of densely packed lymphocytes, receptor
internalisation may influence chemokine concentration only at high receptor numbers.
• With increasing receptor numbers, the sensitivity of a cell is higher but this can be abrogated due
to increased internalisation.
3.3.4 Gradient inversion due to receptor internalization
Chemokine concentration can be disturbed by receptor dynamics as we discussed in the previous sec-
tion. This process may lead not only to a decrease in chemokine amount but in change of the gradient
as well. To model such a situation I constructed a system consisting of 50 stromal cells and 3000 B
cells clusters positioned at a distance of 200 µm between the centres, see fig. 3.24. B cells positions are
fixed, i.e. they do not migrate.
A simulation was performed for 100 min and the chemokine concentration and the gradient at
different space points were calculated. In the case of a receptor number of Rtot = 105, there was no
gradient inversion observed, see fig. 3.25 (top panel). However, at higher receptor numbers of Rtot =
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Figure 3.24: A model system of 50 stromal and 3000 B cells positioned in clusters with
the distance of 200 µm between their centres.
106, the chemokine field was disturbed and the gradient was inverted in the area of the lymphocyte
cluster, i.e. a cell being positioned at the farther side of the B cell cluster would migrate to the direction
opposite to the stromal cell cluster, fig. 3.25 (bottom panel).
Given that a very high receptor density (106 per cell) was needed for gradient inversion in the
simulation set-up, even for a rather big B cell clusters (3000 cells), gradient inversion seems to be not
achievable in vivo for CXCL13. However, the affinity of CXCL13 is one order less than, for example, the
affinity of CXCL12. Thus, a disturbance of the gradient profile due to chemokine consumption could be
observed for other types of chemokines. Our framework allows to investigate such possibilities if there
are available data on receptor dynamics and chemokine diffusion.
Conclusion
• High receptor number might results in chemokine gradient inversion, however it demands high
receptor densities in the case of CXCL13.
3.3.5 Simulation of lymphocyte clustering
Having implemented the collision detection algorithm, the description of chemokine diffusion and the
receptor dynamics, one can model events of stromal cell activation and lymphocyte clustering. For this,
I constructed a model consisting of stromal cells positioned randomly with the same density as in the
case of simulation of the contact frequency in section 3.3.2. The stromal cells were located around a
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Figure 3.25: Gradient representation for the system from fig. 3.24 for a case of 105 (top
panel) and 106 receptors/lymphocyte (bottom panel). The lines are directed along with the
chemokine gradient. The density of lines is not connected with the gradient intensity, but
is chosen for a better view of the gradient direction in the inter-cluster area. For rendering
of cell distribution and chemokine gradient the Python interface to Mayavi software was
used [175].
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Figure 3.26: Simulation of lymphocytes (blue) influx from the blood vessel into the tissue.
Having achieved the threshold signal value (θ = 30), stromal cells get activated (yellow)
and start to secrete CXCL13. Non-activated stromal cells are not shown due to their high
density. In the beginning of the simulation there are no activated cells (left, 500 min).
Gradual increase in lymphocyte density results in development of clusters (right, 5000
min).
“blood vessel” with a diameter of 10 lymphocyte diameters (dvessel = 120µm). The perivascular area
was limited to the radius of 400µm in the cubic simulation box of 1540µm x 1540µm x 1540µm size.
B cells appear in the simulation box via the blood vessel and randomly migrate in the tissue. Upon a
contact with a stromal cell, the B cell is stopped for 1 min and continues its migration after then. The
stromal cells integrate the abstract signal from contacts with lymphocytes. The signal decays with the
rate dS = 1/(20min). I assumed the frequency of B cell entrance to be 0.5 cells/min which allows to
achieve signal values of 10-20 during the simulation. For the activation threshold I used θ = 30.
In these conditions, stromal cells get activated when the concentration of lymphocytes will increase
sufficiently or because of random fluctuations in lymphocyte distribution. The result of these simula-
tions is represented in fig. 3.26 after the first 500 minutes after simulation start (left) where no clusters
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or activated cells are observed (non-activated cells are not shown for better view). However, due to
higher contact frequency in the perivascular area, after 5000 minutes several clusters of activated stro-
mal cells (yellow) and lymphocytes (blue) were observed adjacent to the blood vessel, see fig. 3.26
(right).
Although I can now reproduce cell clustering in the context of stroma activation due to the lym-
phocyte influx from the blood vessel, these simulations are based on qualitative assumptions about cell
signalling. Additional information about how many contacts are needed to upregulate CXCL13 secre-
tion or how much time the memory about interaction lasts would give the opportunity for more realistic
simulations.
Agent-based modelling has an advantage in comparison to ordinary differential equations which
are also used for description of cell populations, because in such frameworks the spatial aspect is also
considered. To illustrate it, I performed a simulation for the same set-up but with a lower threshold
value θ = 10 and having 6000 B cells randomly scattered in the simulation box. As it can be expected, in
the beginning of the simulation stromal cells will get activated ubiquitously (fig. 3.27, up-left), however
because not all the cells get activated simultaneously and there are fluctuations in the density due
to random positioning, there are locations with higher concentrations which will attract lymphocytes
from the neighbouring activated stroma regions. This will result in development of bigger clusters
(fig. 3.27, up-right) which trap lymphocytes from smaller ones. Consequently, the lack of contacts in
these neighbouring stroma areas will decrease the number of activated stromal cells or will result in
their dissolution, as can be seen from the overshoot at the bottom plot, fig. 3.27. This kind of effect
can be observed only due to description of spatial localisation of participating cells and can not be
reproduced by an ordinary differential equation model. Although it is modelled in an artificial set-up,
these results raise the question whether it is possible to observe fusion of clusters or cell trapping from
neighbouring activated regions in vivo.
Lymphocyte density directly influences the probability of stromal cells to get activated because
higher B cell densities allow more frequent contacts with the stromal cells. I performed simulations
for a range of lymphocyte density and activation threshold when stroma activation is observed or not
observed throughout the simulated period. In the beginning of the simulation B cells were positioned
randomly in the simulation box and their number was constant due to periodic boundary condition at
all three axes. If any stromal cell is being activated, the simulation is stopped. Otherwise, the simula-
tion is stopped after 10000 minutes. In agreement with section 3.3.1, the expected activation time was
dramatically increasing with the decrease of B cell density and at low B cell numbers the were only few
activation events observed, fig. 3.28. More detailed knowledge of activation mechanisms might help to
estimate probabilities of stroma activation in order to optimise anti-CD20 immunosuppressing therapy.
Not only lymphocyte density could influence stroma activation, but their motility as well. For the
same system, I computed activation times for various B cell speed values. The activation time appeared
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Figure 3.27: An illustration of cluster fusion under the condition of a low activation
threshold value (θ = 10). 6000 lymphocytes were randomly positioned in the simula-
tion box before the start of the simulation. In the beginning, stromal cells get activated
ubiquitously (top left panel), however, bigger clusters trap lymphocytes from the neigh-
bouring activated stromal cells with the result of small cluster dissolution or their fusion
with the bigger ones (top right panel). The number of activated stromal cells during the
simulation (bottom panel).
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Figure 3.28: Heatmap of frequency of stroma activation for varying activation threshold
value and lymphocyte density. For every parameter set, 20 simulations were performed
for the time period of 10000 minutes and dS = .01min
−1.
to depend non-monotonically on the speed: the time was shorter for slow and high speeds, fig. 3.29,
left. In average, lymphocyte-stroma contacts are more frequent for a higher lymphocyte speed, which
results in shorter activation time. If the speed is low, there are less contacts in the system in total.
However, if the persistence time remains the same for all simulations, in the case of low speed, it takes
more time for lymphocytes to leave a neighbourhood of a contacted stromal cell, which may increase
a probability of repetitive contacts, and, hence, stroma activation. It is interesting, that the activation
time is different for the case of rectangular packing of stromal cells, fig. 3.29, right. This results need
additional investigation in order to understand in details how the activation time depends on the system
architecture and whether it is a result of any model artefacts. I do not perform such an analysis here,
but plan it for the future work.
Conclusion
• The framework is able to reproduce cluster development in the area of a blood vessel.
• Data about stroma activation are needed in order to fit the model of signal integration.
• The modelling framework allows to grasp spatial effects in a system of chemosensing cells and
shows the possibility of cell cluster fusion into bigger clusters.
• B cell density is an important factor for control of stroma activation and investigation of activation
mechanisms might have efficient clinical implications.
• Cell motility may contribute to control of the activation time of stromal cells.
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Figure 3.29: Activation time of stroma as a function of B cell speed for random uniform
(left) and rectangular stromal cell positioning (right). For every speed value, 70 (random
positioning) or 20 (rectangular positioning) simulations were performed up to maximal
time of 10000 minutes. Small random disposition is added to the points in order to avoid
overplotting for better representation.
3.4 Discussion
In this chapter I present the framework for modelling cell interaction and migration in the context
of early TLO development. Unfortunately, the exact mechanism which is responsible for stromal cell
differentiation is not known and I substituted it by a phenomenological model of signal integration
in the section 3.3.1. Such a straightforward approach illustrates that in a certain range of contact
frequency and time of contact memory, the first passage time can dramatically depend on slight changes
in the contact frequency. If there will be experimental data on stromal cell activation by contacts with
lymphocytes, it will allow to predict probabilities of the development of a pro-TLO environment during
a given time period. Up to now, the main treatment during chronic humoral rejection is the therapy
directed against B lymphocytes (anti-CD20 antibodies, or Rituximab). Depletion of B cell counts in
the organism may prevent B cell-mediated responses as well as delivery of the activation signal to the
stroma via contacts with B cells. However it has side-effects. Mathematical modelling may help to
optimize the dosage of such treatments and reduce non-favourable side effects or adjust therapy in a
way that lymphocyte concentration is below the critical density.
Due to its simplifications, the approach used in section 3.3.1 lacks a spatial component, which can
be important in the context of cell migration, as we discuss in the section 3.3.2. In the system of lym-
phocytes entering the tissue via a blood vessel, one may see that stromal cells located closer to the
vessel receive contacts with a higher frequency. In order to perform such kind of simulations, one needs
to efficiently handle cell movement and collision. For this purpose, I developed the 3D agent-based
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framework which uses a sweep-and-prune algorithm for collision detection and phenomenological im-
plementation of physics only with the purpose of avoiding cell-cell penetration. Such kind of problems
are rather frequent in biology currently and the code may be used in other projects where spatial data
are available from microscopy or biopsies.
Not only the physical contact plays a role in cell interactions during TLO development but
chemokine-mediated interactions as well. I showed that a single cell can generate gradients which
can trap lymphocytes at a distance of 50µm only if the receptor density and the secretion rate are
rather high (105 and 105 molecules/min, respectively). This kind of results may be transferred to the
level of clusters of activated stromal cells, which allows to estimate a maximally possible trapping dis-
tance, and, hence, a B cell cluster size. Such computations can be validated when compared with biopsy
data about cell distribution.
There are different factors which influence the chemokine concentration. Some of them do not
change it dramatically, for example, the degradation via proteolysis does not substantially decrease the
concentration of CXCL13 in the vicinity of a secreting cell. However, the consumption of chemokines
due to receptor internalisation may result not only in a decrease of concentration, but also in gradient
inversion. This can happen especially for receptor-chemokine pairs with a higher affinity than CXCL13-
CXCR5 (e.g. CXCL12-CXCR4).
One can influence cell migration by control of the number of available receptors or chemokine
molecules. The estimation of the trapping ability by stromal cell clusters described above can help in the
development of anti-chemokine or anti-receptor therapy. Another approach which was also suggested in
clinics is based on the opposite idea: instead of decreasing the chemokine concentration, one may use a
receptor antagonist, which might decrease the number of receptors available for signalling and, hence,
would make cells blind to chemokine gradients. All described approaches can be modelled within our
framework, and having measured kinetics data of receptor dynamics and chemokine diffusion in the
context of, for example, graft tissue, one may estimate how much of a treatment agent is needed to
destabilize cluster formation.
The lack of data about how many contacts are needed in order to activate stromal cells and how
frequent they should be does not allow to predict the probability of cluster formation if one has cer-
tain assumptions about the B cell influx. Ideally, such an experiment should be performed by direct
observation of stroma differentiation when different concentrations of lymphocytes are applied. How-
ever, implicit inference about this process can be made via comparing lymphocyte densities for biopsies
harbouring TLOs and biopsies that are free of TLOs, although it may vary significantly between patients.
Overall, the presented model is useful in two ways: as a methodological workflow, which can be
applied for other systems of migrating cells, and as an instrument for prediction of cluster stability
depending on the applied conditions and system parameters.
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4Modelling of germinal center interactions
4.1 Background
Germinal centres (GCs) are structures located predominantly in secondary lymphoid tissue, although
matured GCs can be found in TLOs as well, as discussed in chapter 1. GCs were discovered in 1884 by
W. Flemming and were thought to be the sites of lymphocyte development. Only later analysis of single
GC cells showed that in GCs B lymphocytes are subject to somatic hypermutations (SHM) and selection
based on the affinity of the B cell receptor (BCR) to the antigen, i.e. GCs are responsible for the so-
called affinity maturation process. The biology of GCs was previously described in the classical work
of MacLennan [132] and more recently in a very comprehensive review by Victora and Nussenzweig
[213]. In this chapter I construct a model of the interaction of different GCs. Hence, I briefly introduce
the main cellular events which happen during the process of affinity maturation, or GC reaction (GCR).
GCs can be functionally and anatomically divided into two regions, the dark (DZ) and the light zone
(LZ) [155], fig. 4.1. B cells in the DZ are called centroblasts. They extensively proliferate and are
characterised with a very high division rate with a cell cycle in the range of 6-12 hours. Centroblasts
share the same morphology and cell size with centrocytes, B cells of the LZ, and these cell types can
be distinguished only by difference in expression of surface markers such as CD86, CD83 and CXCR4
receptor [213]. The phenotype of B cells is regulated by the Bcl-6 gene (Bcl for B cell lymphoma) and
deficiency in this gene results in the absence of GCs [50]. According to [213], Bcl-6 is responsible for
several functions:
• suppression of anti-apoptotic gene Bcl-2 impacts on the B cell survival and selection;
• suppression of p53 and ATR increase cell tolerance to DNA damage due to extensive SHM and
division;
• regulation of B cell exit from GCR via inhibition of Blimp-1 expression;
• regulation of selection signals via suppression of CD40 and BCR expression.
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Figure 4.1: The anatomy of GC. The B cell follicle (blue) contains a germinal centre
with the dark zone where GC B cells (green) proliferate and mutate and the light zone
containing the network of follicular dendritic cells (FDCs, red), T folicular helper cells and
other cell types (not stained). Interactions of B cells with FDCs and Tfhs lead to B cell
selection in terms of higher affinity to the antigen. Adapted from [213].
Disregulation of B cell fate decisions may result in lymphoma or autoimmunity [157]. In addition, GC
B cells express AID which induces VDJ gene rearrangements and SHM in the BCR and together with the
high division frequency results in high numbers of new B cell clones [9, 84, 124, 231]. The population
of generated clones is constantly tested in interaction with cells from the LZ.
Follicular dendritic cells (FDCs) function was reviewed in chapter 1, retain antigen at their surface
in the form of immune complexes, i.e. antibodies bound to antigen. FDCs are able to retain antigen for a
very long time and, although affinity maturation was observed even in their absence, they are important
for immune responses in suboptimal conditions when the amount of antigen is limited [184]. They are
characterised by expression of complement receptors the CR1 and CR2 participating in the presentation
of antigen to GC B cells as well as of adhesion molecules like VCAM-1 and ICAM-1 which are important
for the formation of immunological synapses with B cells, fig. 2.5. FDCs sustain surveillance of GC B
cells by secretion of BAFF. They are also responsible for B and T cell positioning due to secretion of
CXCL13, a ligand for CXCR5 receptor located at the surface of GC B cells and T follicular cells (Tfhs).
LZ B cells collect antigen located on the surface of FDCs and present it to Tfhs (T follicular helper cells)
as MHC-II-peptide complexes [47, 133].
Analysis of the migration patterns and of individual mutations in B cell clones resulted in the pro-
posal of a cyclic-reentry model by [100], in which B cells are involved in several rounds of proliferation
and selection. Having passed selection in the LZ, B cells either recycle back to the DZ and continue
division and SHM or differentiate to plasmablasts (PBs) or memory cells. According to an alternative
model, all B cells return to the DZ where the fate decision takes place [55, 141].
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The mechanisms of this fate decision are not clearly known yet. By default, GC B cells are pro-
grammed to die by apoptosis [123] and upon successful interactions with FDC and Tfh, they may be
rescued from cell death. The contribution of interactions with FDCs via BCR to the selection process
is still unclear and in [213], T cell help is hypothesized to be the limiting factor in the GCR based on
theoretical and experimental investigations. Tfhs were shown to interact with several GC B cells at the
same time and they are able to polarize towards the cell bearing higher density of antigen-MHC com-
plexes at the surface. In experimental setup where B cells were artificially loaded with antigen using
antigen-antibodies fusion proteins, Tfhs were selecting these cells irrespective of their affinity, and, as a
result, affinity maturation was disrupted [214]. Since cells with higher affinity BCR have an advantage
in collecting antigen and hence in presenting it to Tfh [22, 51], this two-step selection system allows
to increase the average affinity of B cell clones during the GCR [58, 59]. Although the critical role of
Tfh in B cell selection was shown, what signals influence the further B cell differentiation to antibody
secreting PBs or to memory B cells is not discovered yet.
Figure 4.2: Schematic representation of the GC reaction. BDZ, BLZ correspond to B cells
in the dark and the light zones; T to Tfh; BFDC, BTC are B cells in interaction with FDC and
Tfh, respectively; O is an “ output” B cell after interaction with Tfh; P are PBs. Memory B
cells are not considered in this study. Antibodies (orange molecules) are produced by PBs
and can penetrate the GC and bind the antigen presented on the surface of FDCs.
GCs are predominantly discussed as isolated structures. However it is interesting to investigate how
they might interact with each other. Recently, Tfhs were shown to migrate between different GCs [190],
but besides cellular interaction, there might be communication mediated by molecules. Antibodies
produced by PBs from one GC may penetrate the same and other GCs and bind to the antigen presented
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Figure 4.3: Secreted antibodies penetrate the GCs itself as well as other ones what
results in antigen masking at the FDCs surface influencing antigen access for B cells.
on the FDC surface [232], fig. 4.3. This disturbs recognition of the antigen by low affinity B cell clones,
increasing the selection pressure during the GCR and changing the reaction kinetics [232]. In the light
of these results, it is interesting to investigate how GCs may influence each other in terms of the GCR
kinetics and how the affinity maturation changes depending on the system size or the starting time
of the GCR. I constructed a model describing GCR kinetics using ordinary differential equations and
compared the development of the immune response in different simulation setups.
4.2 Mathematical model
Representation of clones and mutations
There are several published models of the GC reaction based on systems of ordinary differential equa-
tions (ODE) [101, 138] or agent-based approaches [62], but none of them considers GCs as a system
of interacting instances. In our model, cell dynamics and chemical kinetics of antibody-antigen binding
were described with a system of coupled ODE. I used the phenomenological concept of 4 dimensional
shape space to describe clones of different affinity, see for example [138]. In this representation, a
clone is coded with 4 integers which might correspond to some physical properties of the B cell recep-
tor, and a mutation corresponds to one step in any direction in the shape space. This approach allows
to describe the dynamics of clones with different affinities, although this simplified representation is
not based on any measurable mapping of sequences to affinities. Our model has to be considered as a
qualitative approach rather than a precise predictive model in this respect. The simulation starts with
clones located at a distance of 5 mutations from the optimal clone [140]. The number of clones located
at the distance of not more than 10 mutations from the optimal clone is 104 for a 4D shape space. To
simplify our calculations, I substituted numbers of clones located at equal distance by their total num-
ber, i.e. transformed the system from 4D representation to 1D (similar to models using affinity classes
representation [101]):
B(i) =
∑
~j:|~j−~o|=i
bj , (4.1)
where B(i) is the total cell number of clones located at distance i from the optimal clone ~o, | · | denotes
the Hamming distance, and bj is the number of cells of clone ~j.
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In the discrete 4D space, not all clones at the same Hamming distance are located in the same
configuration. For example, assuming {0, 0, 0, 0} as the optimal clone, 7 possible mutations of the clone
{2, 0, 0, 0} lead to a lower affinity configuration and 1 mutation leads to a higher affinity clone {1, 0, 0, 0}
(i.e. smaller distance to the optimal clone). In contrast, for the clone {1, 1, 0, 0}, which has the same
Hammings distance as {2, 0, 0, 0}, only 6 mutations lead to lower affinity and 2 to higher. In Fig. 4.4 the
corresponding situation is illustrated for a 2D case. For every configuration, the exact number of such
transitions to higher and lower affinity can be calculated. Since all numbers of the clones located at
the same distance were substituted by their total number B(i), I calculate the total number of possible
transitions from all configurations located at the distance i to higher (t+) or to lower (t−) affine states
to estimate which proportion of cells of B(i) mutate to a higher or lower affinity state. With p being
the proliferation rate, m the mutation probability, and assuming equal probability for all mutations, the
rate of transitions i+ 1→ i reads
t−(i+ 1)
t−(i+ 1) + t+(i+ 1)
pmB(i+ 1), (4.2)
where t±(i + 1) is the number of possible transitions from i + 1 to higher (+) or lower distance (–).
t+ can be computed iteratively as t+(0) = 8, t+(1) = 8c1 − t+(0), . . . , t+(k + 1) = 8ck − t+(k), and
t+(k) ≡ t−(k + 1), where ck is the number of clones in the shape space which are located at a distance
k from the optimal clone
ck =
min(4,k)∑
l=1
Cl−1k−1 · 2l · Cl4, (4.3)
where Ckn =
n!
k!(n−k)! . Having the numbers of cells for clones i ± 1 the number of cells to mutate into
the clone i becomes
N(B(i− 1), B(i+ 1)) = t−(i+ 1)
t−(i+ 1) + t+(i+ 1)
B(i+ 1)︸ ︷︷ ︸
i+1→i
+
t+(i− 1)
t−(i− 1) + t+(i− 1)B(i− 1)︸ ︷︷ ︸
i−1→i
(4.4)
Cell interactions
The rate gFDC of contact formation of B cells with FDCs is proportional to the number of available sites
with antigen. I assume that every FDC has 6 sites (like cube sides). With 200 cells the total number of
FDC sites is estimated as #(FDC sites) = 200× 6 = 1200. Not all sites are used simultaneously and the
system is not sensitive to this parameter. Hence, a precise estimation of the FDC network interaction
capacity is not necessary. I assume that a B cell is not able to interact with a certain site on an FDC if
another B cell has already occupied it or the antigen is masked with antibody of higher affinity than that
of the BCR. A cell which has a high affinity is assumed to have a higher probability of interacting with
an FDC. This is implemented by weighting the rate of contact formation gFDC with the function ρ(i),
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Figure 4.4: Example of clone configurations. Different configurations of clones on a
2D grid lead to different numbers of transitions to higher and lower affinity. The red circle
is the optimal clone, the blue circles are the clones located at a distance of 2 mutations
from the optimum. The red arrows show beneficial mutations, while black arrows show
mutations leading to lower affinity to the optimal clone.
which monotonically increases with affinity. Within these assumptions, the rate of interaction becomes
g FDC(i) = g
0
FDCρ(i)α(i)
#( FDC sites)−∑iB FDC(i)
#( FDC sites)
G
G0
, (4.5)
where g0FDC is the rate of contact formation in the absence of antigen masking and when all sites are
free, α(i) is the proportion of antigen available for clone i, i.e. free antigen and immune complexes
with antibodies of lower than i’s affinity, ρ(i) = exp(−i2/2.82) is the affinity function defined in [140],
and G, G0 are current and initial antigen amounts respectively. The rate of interaction with Tfhs is
described in an analogous way:
g TC(i) = g
0
TCβ(i), (4.6)
where g0TC is the rate of contact formation if all Tfhs are free.
It was shown in [51], that T cells do not distinguish between B cells of different affinities, but
preferentially interact with B lymphocytes presenting more antigen on their surface. I assume that B
cells with higher affinity collect more antigen [142, 214] and that the probability of interaction with
Tfhs β(i) is proportional to the number of free Tfhs plus the number of Tfhs in interaction with lower
affinity than corresponding to clones i
β(i) =
#( Tfh)−∑j≤iBTC(j)
#( Tfh)
. (4.7)
This probability enters Eq. 4.6.
Since the threshold of entrance into the GC in the beginning of the reaction is low [188], I assume
that any interaction with FDC leads a B cell to the next selection step independently of its affinity. The
only difference between clones at this stage is the probability ρ(i) to be involved in an interaction in
Eq. 4.6.
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The kinetics are modelled based on rate equations. The model distinguishes two morphological
zones which are associated with the presence of B cells of different phenotypical characteristics [107].
The cells which are located in the DZ (BDZ(i)) proliferate with rate p and differentiate to the light zone
(LZ) phenotype with rate gLZ. At every division, a cell mutates with probability m as its neighbours
do. The number of neighbours is defined by Eq. 4.4. Output cells O(i) are selected for recycling with
probability (1− r). After one division (factor 2 before (1− r)) they return to the BDZ state:
B˙DZ(i) = (p− 2mp− g LZ)BDZ(i) + pmN(B(i− 1), B(i+ 1)) + 2(1− r)pO(i) . (4.8)
B cells in the LZ die via apoptosis with rate d and interact with FDCs with rate gFDC:
B˙LZ(i) = g LZBDZ(i)− (gFDC + d)BLZ(i) . (4.9)
The cells that interact with FDCs BFDC(i) turn to the “FDC selected” state B∗(i) with rate hFDC, which
was derived from the average duration of interaction:
B˙FDC(i) = gFDCBLZ(i)− hFDCBFDC(i) . (4.10)
The cells in the state B∗(i) search for Tfhs and die with a decreased apoptosis rate dselected:
B˙∗(i) = hFDCBFDC(i)− (gTC + dselected)B∗(i) . (4.11)
In analogy to the interaction with FDCs, interaction with Tfh (BTC) induces differentiation to the output
state O(i) with rate hTC:
B˙TC(i) = gTCB
∗(i)− hTCBTC(i) . (4.12)
Output cells O(i) divide with the same rate p as the DZ cells and differentiate to PBs with the probability
r or go back to the DZ otherwise (see Eq. 4.8):
O˙(i) = hTCBTC(i)− pO(i) . (4.13)
PBs die with apoptosis rate dP :
P˙ (i) = 2rpO(i)− dPP (i) . (4.14)
At each interaction with an FDC, an amount q of antigen is consumed:
G˙ = −
∑
i
qhFDCBFDC(i), (4.15)
where G is the antigen concentration, hFDC is the rate of interaction of a B cell with an FDC, and
BFDC(i) is the number of B cells at Hamming distance i in interaction with an FDC (see Eq. 4.10).
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Antigen masking is calculated in equilibrium of immune complexes and antibodies produced by PBs:
A˙(i) =
ns
Vblood
P (i)− dAA(i) (4.16)
C(i) =
A(i)Gfree
Ki +Gfree
(4.17)
G = Gfree +
∑
i
C(i) (4.18)
Ki := 10
−5.5−0.4(10−i)), (4.19)
where A(i) is the concentration of antibodies, C(i) is the concentration of immune complexes, Ki is the
dissociation constant, dA is the antibody decay rate, s is the secretion rate of antibodies for a single cell,
Gfree is the concentration of free antigen, and n is the number of GCs in the range of 300-500 [95]. I use
n = 300 to investigate whether inter-GC interaction via antibodies is still observable at lower numbers
of GCs. For higher numbers n, the effect of inter-GC interaction is more pronounced. I assume that
antibodies are present in excess to antigen in GCs. Otherwise the immune response would be inefficient
because a significant part of antibodies would be bound to antigen in GCs but not to a pathogen. If the
concentration of antigen is very low, the ratio [free antigen]:[immune complex] becomes
Gfree
C(i)
=
Ki
Ai
. (4.20)
Since only the percentage of antigen bound in complexes is relevant, I can use an arbitrarily small value
for the initial G0 = 10−16M. The size of antigen quanta enters the fitting routine.
The immune power (IP) metric is defined as the percentage of the antigen which would be covered
with antibodies of given concentrations. For the calculation of IP values I use the concentration of
antibodies produced by one GC multiplied by n = 300. The choice of the antigen concentration is
arbitrary and is chosen as G = 10−6M for presentation reasons. Then, the concentration of unbound
antigen Gfree can be calculated and determines the fraction of bound antigen to
IP =
G−Gfree
G
. (4.21)
Parameter fitting
For most of the parameters, values from experiments or theoretical estimations were used (Table 4.1)).
The model was fitted to experimental measurements of GC size [204] by minimizing the residual sum
of squares (RSS) [219] using the C++ library for nonlinear optimization NLOPT (Steven G. Johnson,
http://ab-initio.mit.edu/nlopt), Fig.4.5. To incorporate data about antigen consumption to the
fitting I modified the RSS function by adding a weighted term
RSS∗ = RSS + w ·
(
Aend
A0
− 0.25
)2
, (4.22)
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Figure 4.5: Model fitting. Result of model fitting to GC size kinetics from [204]. Mono-
clonal expansion period (dashed line) is followed by the established GC (solid line).
where I assume that Aend, the amount of antigen in the end of the GC reaction, should be approximately
one quarter of the initial antigen amount A0 according the antigen kinetic data [200]. The value
w = 100 was found to be appropriate in the sense that the system follows the dynamics of GC size but
does not run out of antigen. The first 3 days are described by exponential monoclonal expansion with
proliferation rate p. The simulation of the GC reaction after expansion starts with 10000 cells which is
based on the assumption that the radius of a GC is 160µm, the average B lymphocyte cell size is 15µm
[209], and that the GC cells are densely packed.
Antigen quanta q, the rate of BCs to get LZ phenotype gLZ and the rate to find an FDC gFDC are the
fit parameters. The 95% confidence intervals (CI) were calculated using nonparametric bootstrapping
[40]. For the parameter g0FDC the CI is (0.43,2.3) and for gLZ the CI is (0.13,0.22). Antigen quanta and
gFDC are mutually dependent parameters, since the larger antigen quanta is, the less frequently B cell
should interact with FDCs in order to keep antigen amount in an appropriate range. That is why I fixed
the value of antigen quanta and estimated the CI only for gFDC.
Estimation of B cell-Tfh interaction rate
The rate of contact formation between B cells and Tfh g0TC in Eq. 4.6 was approximated based on
constraints on the mean free path length. The speed of lymphocytes is vBC = 8µm/min [143, 220] and
the concentration of Tfh is nT = 104cells/mm3 [190]. For a B lymphocyte with a diameter of 15µm
[209] and a T cell with a diameter of 8.5µm [93], the mean free path of a B cell between interactions
with Tfh gets
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Table 4.1: Model parameters.
Notation Meaning Value Unit Reference
Vblood blood volume 4 ml [232]
s antibody production rate 2× 10−18 1/hr/cell [177]
p proliferation rate log 2/6 hr−1 [58]
gLZ rate to get LZ phenotype 0.15 hr
−1 fitted
g0FDC rate to find FDC 0.61 hr
−1 fitted
g0TC rate to find TC 3 hr
−1 estimated
d apoptosis rate 0.1 hr−1 [122]
h FDC rate of interaction with FDC 2 hr
−1 [211]
h TC rate of interaction with Tfh 2 hr
−1 [142]
r probability to differentiate 0.2 [141]
dSelected apoptosis rate of activated cells 0.02 hr
−1 [138]
dP PBs apoptosis 1/4 day
−1 [99]
dA antibody decay log 2/10 day
−1 [232]
q antigen quanta 4.6× 10−21 M−1 fitted
FDC number 200 cells [62]
FDC dendrites pro cell 6 [142]
n number of GCs 300 [95], see text
λ =
1√
2σnT
=
1√
2pi · (7.5 + 4.25µ m)2 · 104cells/mm3 = 0.163mm [38] (4.23)
τ Tfh =
λ
vBC
=
0.163mm
8µm/min
= 20min⇒ 1
τTfh
= 3hr−1 ≈ g0TC, (4.24)
where σ = pir2BC is the cross section of a lymphocyte, τTfh is the free path duration.
It is difficult to estimate the rate of interaction with FDC directly because FDCs form a network of
dendrites and B cells need to collect multiple portions of antigen what leads to a sequence of multiple
interactions with different FDCs. Therefore the rate gFDC was treated as a fit parameter.
4.3 Results
How to compare the efficiency of humoral immune response in silico?
GCs generate antibody forming plasma cells. The produced antibodies are supposed to bind fragments
of the pathogen and either neutralize or opsonise it. The efficiency of this process depends on antibody
concentration and affinity of the antibody for the antigen. With the aim of comparison of GCs I define
a new measure of GC efficiencies in binding pathogenic antigen. I consider the limit of antibodies in
excess of antigen and use classical chemical kinetics to determine the fraction of bound antigen. For a
concentration of antibodies equal to its dissociation constant K, half of the antigen is bound in immune
complexes. To cover the same percentage of antigen with antibodies of K/10 affinity, the required
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antibody concentration is 10 times higher. Both these results of a GC reaction are considered of equal
efficiency because the same fraction of antigen is bound.
In the spirit of this simple thought, I propose to use the percentage of antigen bound by GC derived
antibodies as a measure IP for the efficiency of the GC reaction
IP =
[antigen in complex]
[total antigen]
, (4.25)
where the brackets denote concentrations and IP stands for “immune power”. The total antigen con-
centration for computing the IP can be chosen freely and may be adjusted to optimise the illustration
of results.
During GC simulations, the IP is continuously computed in order to generate a time course of GC
efficiencies in binding antigen and to compare the strength of immune responses in different GC mod-
els. Since the model does not distinguish neutralizing and non-neutralizing antibodies, the IP is a
simplification which restricts the analysis to functional antibodies.
Strong selection pressure does not guarantee efficient immune responses.
Antibodies derived from GC reactions diffuse over the whole organ. Antibody feedback was shown
to influence selection during GC reactions [139, 232]. Masking of antigen by antibodies increases
selection pressure and might prevent access of low affinity B cell clones to antigen. At the same time
higher selection pressure induced by high-affinity antibodies might reduce the number of PBs that leave
the GC.
These adverse effects of antibody feedback on the GC motivate the question how the strength of
antibody feedback would impact on GC efficiency in terms of IP. The strength of antibody feedback can
be modulated by tuning the number of GCs. This is equivalent to scaling the antibody productivity of
PBs. In the reference system, 300 GCs were assumed. For a system with reduced antibody feedback the
number of GCs was reduced to 30, which reduced the amount of antibodies competing with GC B cells
for antigen correspondingly.
The difference in selection pressure was reflected in the GC population kinetics (Fig. 4.6A). With re-
duced selection pressure, a regrowth of the GC B cell population was observed due to lack of adaptation
of the antigen coverage to the progress of affinity maturation of B cells.
With reduced selection pressure, the average affinity of PBs gets lower as well (Fig. 4.6B), but the
number of PBs (not shown) and the IP per GC is higher (Fig. 4.6C).
The plasma cell number, and therefore the antibody concentration depend on the number of GCs in
our system. To test how the IP changes with the amount of antibody produced, I performed simulations
from 1 - 1000 GCs. In addition, for every number of GCs N I compute the IP for a system of a single
GC which is scaled to the system of N GCs, i.e. I multiply concentration of antibodies by N during
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Figure 4.6: Influence of antibody feedback onto GC dynamics. A-C: Total cell number,
average PB affinity and the IP for GCs developed in condition of normal (full lines) and
reduced (dashed lines) antibody feedback. The strength of antibody feedback was modu-
lated by the number of simultaneous GCs. The IP corresponds to a system of 300 GCs and
is scaled appropriately in case of 30 GCs. D: The total IP depending on the number of GCs
(solid line), where more GCs mimic increasing antibody feedback, is compared to the IP of
a single GC scaled to the corresponding number of GCs (dashed line).
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IP calculation. If there is only one GC in the system the feedback of antibodies is minimal, hence
comparison of the IPs between the system of N GCs and the IP of the single GC system scaled to the
same size allows us to see how GC-GC interaction influence the efficiency of the immune response.
Although the IP monotonically increases with the GC number, the feedback effect increases as well (the
difference between the solid and the dashed lines in Fig. 4.6D), further limiting the contribution of each
GC.
Late developing GCs are suppressed by early ones.
Antibodies derived from one GC can penetrate all GCs in the organism. Next, I asked whether this
interaction supports or suppresses the emergence of late GCs. I considered a model with 300 GCs
which started simultaneously under normal conditions and one GC which was initiated 3 days later
than the others. The later appearing GC develops under the influence of antibodies being generated by
the other 300 GCs, and I monitored its affinity maturation, PBs and IP.
The simulations suggest that early GCs boost late GCs in terms of affinity maturation. Since antigen
masking by antibodies from the early GCs increases the selection pressure in the late GC, a higher
average affinity of PBs is found (Fig. 4.7B). However, in terms of cell numbers the late GC was strongly
suppressed (Fig. 4.7A). As a consequence, the IP of the late GC is decreased as well (Fig. 4.7C).
I varied the time of the delay and found that late GCs do not contribute to the immune response
significantly: the IP of a GC started 5 days later is only around 10% of the early GC(Fig. 4.7D).
Simultaneous development of GCs is more beneficial
The GC response may be delayed, for example, in the neonatal organism where the FDC network is still
developing [166] or in the aged organism where antigen transport is impaired [105]. It is interesting
how such delays in the GC development may influence the efficiency of the immune response. In this
section, I focus only on the influence of the starting time of a GC reaction on its dynamics without
consideration of case specific factors like changes in antigen transport with age or the process of FDC
maturation in neonatal mice.
I compared two different cases: a) a “simultaneous” model with start of 300 GCs at day 0; b) a
“sequential” model, in which 30 new GCs start every day during 10 days. The initial amount of antigen
in newly developed GCs was set to the current amount of the antigen in the GCs developed at day 0.
The first 30 GCs in the “sequential“ case are developing under reduced antibody feedback, which is
identical to the simulation in Fig. 4.6. They generate more antibodies and cells in comparison to the
“simultaneous“ system. However, this is not enough to compensate for the suppression of the later GCs,
because the overall IP for the ”sequential“ system appeared to be lower, Fig. 4.8. This result shows
that delays in GC reaction result in poorer output even without consideration of additional pathological
conditions which caused this delay.
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Figure 4.7: The impact of retarded GC reactions. A-C: Total cell number, average PB
affinity, and the IP (scaled as in Fig. 4.6) of an early GC (full lines) is compared to a GC
which initiated 3 days later (dashed lines). The graph for the late GC is shifted 3 days
backward for the sake of better comparison. D: The ratio of the IP of the late to the early
GC is shown for increasing delay of the late GC.
4.4 Discussion
GCs are mostly considered as isolated structures. In this study I introduce the first model considering
interactions between different GCs. I show that GCs appearing later contribute little to an immune
response and that the influence becomes negligible with increasing delay. According to this result,
synchronous GC initiation leads to more efficient antibody response than sequential one.
The model provides evidence for an impact of antibody feedback onto affinity maturation and the
size of GC responses. Stronger antibody feedback increases GC B cell affinity but at the expense of the
number of PB generated. Thus, there is a trade-off between quantity and quality of generated output
[139]. In addition, the overall GC population kinetics are strongly influenced by this feedback mecha-
nism as also observed in experiment [232]. The reduced size of late GC reactions over-compensates the
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Figure 4.8: Immune efficiency of simultaneous versus sequential GCs. The development
of the IP over three weeks for 300 simultaneously started GCs (dashed line) is compared
to 30 GCs started every day for 10 days (full line).
positive effect of antibody feedback onto affinity maturation in late appearing GCs, leading to lower IP.
However, the increased selection pressure is able to synchronize B cell affinity between early and late
GCs. Thus, late GCs which would be increased in size by external manipulation are likely to foster the
efficiency of immune responses.
The model predicts that reduced antibody feedback leads to GCs of larger size. Transgenic mice
which are deficient for the secreted form of IgM [57] can be considered as such a system with reduced
antibody feedback. Indeed, these mice exhibit larger GC size in comparison to controls [232]. Part
of the observed effect might be due to prolonged GC reactions as the data were taken 21 day after
immunization. This latter interpretation is consistent with the previous finding that antibody feedback
has a major role in GC shut-down [139].
The desired GC output may well depend on the immune stimulus in question. In the case of a
primary response to infection, it is important to cover as much antigen as possible with antibodies. In
this case, the average affinity of antibodies is not the best measure of response efficiency, since GCs
may generate only small numbers of high affinity PBs to each individual epitope. Thus, the response to
individual epitopes would remain weak. The newly introduced ”immune power” metric, which literally
represents the coverage of epitope by antibodies, is proposed as a better measure of GC efficiency in
antibody responses. In contrast, in the context of vaccination, the aim may be mainly the generation of B
cell memory. It is not clear yet, how specific or diverse an optimal pool of B cell memory cells should be
in order to account for mutated pathogens [78]. The most important value might be the average affinity
of the generated diverse pool rather than the degree of antigen coverage. In this case, optimisation of
the GC conditions based on the average affinity as a metric of efficiency would be beneficial. The model
provides a tool to design conditions of optimisation for both scenarios.
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While the optimal GC efficiency is the result of a subtle balance between affinity and number of
generated PBs, the number of GCs is an important parameter as well. Increasing the number of GCs
has a double beneficial effect: Affinity maturation is accelerated and the total number of generated PBs
is increased. However, the efficiency of individual GC is reduced. Also, the organisms cannot initiate
unlimited numbers of GCs for the limitation of other resources, which are not included in the modelling
approach. According to the simulation results, the organism has to maximize the number of GCs while
preserving a reasonable resource investment.
Our model supports the view that the phase of GC initiation is an essential parameter for the success
of an immune response. The efficiency of simultaneously started GCs is higher compared to a sequential
start of the same total number of GCs. If antigen is not properly provided to lymphocytes, a delay of
GC reactions may be induced, which would lead to a weakened humoral immune response. Fast and
coordinated antigen delivery and GC onset should be considered as a potential mechanism in situations
of suboptimal vaccine response, e.g. the slowly emerging vaccination response in the elderly immune
system [5, 13]. While aged mice quickly produce high titres of low affinity antibody, high affinity
antibody is severely reduced and this is associated with smaller GCs [81, 108]. This may be related to
aged FDC having changes in the efficiency to interact with antibody and immune complex [15], which
could lead to reduced antibody feedback. Furthermore, aged mice respond to vaccination with reduced
numbers of GC, which is thought to be dependent on delayed antigen transport [197].
With the presented model I provide evidence for the need to investigate the interaction of GCs in
order to gain a better understanding of the efficiency of antibody optimisation on the systems level.
Besides antibody feedback, other means of GC-GC interactions like exchange of cells [190] or other
molecules should be considered.
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5Quantification of virus-specific CD8 T cell killing
efficiency in vivo
5.1 Background
Cytotoxic T cells (CTLs) are CD8+ T lymphocytes which participate in the immune response against
infected host cells or cancer cells. CTLs express a T cell receptor (TCR) which recognizes antigens
presented in complex with MHC-I (Major histocompatibility complex of class I) molecules at the cell
surface. If the affinity of such an interaction is high, CTLs stay in contact with the target cell and
secrete granzymes, perforin and granulysin. Perforin molecules form cylindrical pores in the host cell
membrane and also assist in delivery of granzymes into the cytoplasm, which leads to activation of
pro-apoptotic reaction cascades, DNA fragmentation and, finally, target cell death. Additionally, CTLs
express Fas ligand (FasL). Binding of FasL to Fas which is located at the target surface can induce
apoptosis as well [161]. Such so-called effector functions of CTLs allow efficient elimination of infected,
damaged or cancer cells.
The ability of CTLs to specifically recognize and to kill certain cells might be useful in the treatment
of diseases. For example, CTLs which have specificity to tumour antigens may contribute to antitumour
immune response [54]. The efficiency of such adoptive immunotherapy directly depends on the kinetic
characteristics of CTL killing, that is why experimental measurements of CTL killing rate is of high
interest. Following virus infection, transfer of virus-specific CTLs might also be a possible therapeutic
intervention, for example, in cytomegalovirus (CMV)-infected immunodeficient human patients.
There are a number of studies where CTL killing was described in vitro using a chromium assay [28]
or by direct single cell observation [223]. In [223] it was shown that CTLs are very rapid in killing and
may deliver lethal hit to several targets simultaneously. However, until now there were no studies of
in vivo CTL killing models where CTL activity was measured at single cell level and with high spatial
resolution. CTL responses in vivo may differ from in vitro because in the latter, CTLs and targets are
mixed passively, but, in contrast, T cells need to migrate inside tissue in order to reach a target. The
other difference between these experimental conditions is that in vivo there are other cell types present
which may contribute to the regulation of the CTL response.
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Figure 5.1: Microscopy observation of CTLs (green) at the sites of infected with MCMV
cells. A courtesy of Stephan Halle, the group of Prof. Dr. Reinhold Förster, Institute of
Immunology, Hanover Medical School.
In order to estimate killing kinetics of CTLs in vivo, two-photon microscopy was utilized to observe
the behaviour of the target and the T cells in mice infected with murine cytomegalovirus (MCMV).
MCMV-specific T cells were isolated and delivered via intra-lymphatic injection. After one day, infected
cells and CTLs were counted using two-photon microscopy, fig. 5.1. Varying the concentration of in-
jected CTLs and using different cell sorting techniques data about the efficiency of in vivo CTL killing
were collected, fig. 5.2. To estimate the rate of killing I utilized a simple mass-action kinetic model.
5.2 Mathematical Model and Results
Kinetic model
The kinetics of CTL killing were previously modelled using different approaches. I used the simplest
approximation of mass-action kinetics, since the aim of the study was only to estimate the range of
the killing rate but not to investigate spatial effects or to include any additional cell interactions or
proliferation. A similar model can be found also in [144] based on data from Cr release assay, however,
an approximation of enzyme-like reaction kinetics or more complex agent-based approaches were also
applied to the same system [79, 169].
According to the mass-action approximation, the number of infected cell I is described as
dI
dt
= −kTI, (5.1)
where T is the number of T cells and k is the killing rate. This model uses the assumption of a well-mixed
system, where the probability of contacts between T and infected cells are the same and independent
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Figure 5.2: The number of infected cells depending on the CTL number at the day 1 after
CTL injection. CTLs were obtained from wild type mice. Killing efficiency was measured for
CTLs, sorted with different approaches, which allow various purity: Tri-Tetramer- (purity ≈
90%), M45-Tetramer (purity ≈ 60%) and CD26low- enriched (negatively sorted by depletion
of CD26high and CD8− cells). The CTLs from the Perforin−/− knock out mice were used for
comparison as they lack cytotoxic activity. The data were generated at the group of Prof.
Dr. Reinhold Förster, Institute of Immunology, Hanover Medical School
of the previous interactions for a given T and I. The number of infected cells at the time point t is
I(t) = I0 exp(−kT t), (5.2)
where I0 is the initial number of infected cells. I assume apoptosis of target cells to happen only due to
interaction with CTLs, because in control experiments in the absence of CTLs no cytotoxic activity from
MCMV was observed during the time of measurement. The number of T cells is assumed to be constant
as well and I assume that virus spreading between cells is slower in comparison to CTL killing.
The experiments were performed at two different scales with a size of the image frame equal to
400µm x 400µm or 500µm x 500µm, hence I rescaled the numbers of cells to the 400µm x 400µm
experiment. As no killing activity was observed during first 10 hours of the experiment, I assumed the
duration of the experiment to be t = 14hr.
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Figure 5.3: Estimations of the parameter k ([day]−1[cell]−1) and its 95% confidence in-
terval for different experimental conditions.
I assume that the initial number of infected cells I0 is log-normally distributed. In this case the
number of survived cells can be described with the following linear model
log Iexp = log I0 − kT t+ ε, (5.3)
where ε ∼ N (0, σ) is normally distributed.
The killing rates k for every experiment and the initial infected cell number I0 were estimated using
multiple linear regression with R statistical environment [172]. Zero values are considered as censored
measurements and the substitute method was used to treat them [152]. Outliers were detected using
robust regression as described in [146]. I did not impose condition for k to be strictly positive, hence
for the perforin−/− mice estimation of k may reach negative values, fig. 5.3.
In contrast to such a description of the killing kinetics using the k rate, it is more common among
experimentalists to calculate so-called per capita killing rate (PCKR)
PCKR =
I(tend)− I(tstart)
T (tend − tstart) , (5.4)
where I∗ are the numbers of infected cells in the start and the end of the experiment, T is the CTL
number and t∗ are the experiment time points. For our system, the PCKR lies in the range of 2-10
cells/CTL/day. However, the PCKR depends on the CTL number and the duration of the experiment
and I would not recommend to use it for comparison.
Probabilistic model
CTL killing kinetics was also investigated from a probabilistic point of view. For example, in the analysis
of Cr assay data [163] it was concluded that T cells deliver lethal hits at random times (and sequentially,
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CTL number p-value
2 5.7e-01
3 1.7e-04
4 1.3e-02
5 2.3e-02
6 1.2e-01
7 3.0e-01
9 5.8e-01
14 8.9e-01
Table 5.1: The p-value from the binomial test for observed frequencies of CTL killing.
if there are several targets). Here I assume that for a given CTL-target contact there is a certain proba-
bility that the CTL delivers a lethal hit. I used in vivo two-photon microscopy records to estimate if the
number of contacts has any impact on the probability of cell death. If there is no memory, i.e. previous
contacts do not change the probability to die after the next one, then the probability to be killed can be
derived from the probability of death in a single interaction p1. Let a cell gets 3 hits, any 1 or 2 or 3 of
them may be lethal ones with the same probability p1. The probability pdie to be involved in at least one
lethal interaction will be pdie = 1− (1− p1)3 or in general case of n interactions
pdie(n) = 1− (1− p1)n (5.5)
I tested this hypothesis on the collected data on cell death frequency for observed numbers of contacts
using the binomial test, table 5.1. Since the observation of high contact numbers for the same target is a
very rare event, we did not have many experimental data and for 6 and more contacts the hypothesis of
the suggested model is not rejected at the significance level of 0.05. However, for 3 and 4 contacts the
targets were killed with statistically significantly higher probability than expected, hence the previous
contacts with CTLs seem to contribute to the cell death.
5.3 Discussion
Here I implemented simple kinetic and probabilistic models of CTL killing and fitted them to the exper-
imental observations generated from in vivo two-photon imaging. I estimated the killing efficiency of
CTLs for a given experimental setup, which appeared to be in the range of 2-10 cells/CTL/day. There is
no consensus about this value in the community, most probably due to varying experimental conditions.
The frequency of contacts between CTL and target cells depends not on the absolute number of cells
but on their concentrations. For different sites of the body the motility of CTLs may vary as well as the
density of infected cells. These factors will contribute to differences in PCKR and k estimations.
The most interesting result is the analysis of single cell interactions which shows that the process of
killing has memory, i.e. the probability of target cell death depends on its contact history. The probability
increases already after 3 contacts with CTLs. Experimental data about contact times and Ca signalling
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in target cells might give more information about CTL killing activity. Such modelling may describe the
phenomena and invoke new questions and experiments in the CTL biology.
85
6Summary and Outlook
In the previous chapters, I applied mathematical modelling approaches to describe processes in the
immune system. These methods allow to quantitatively estimate parameters of the systems and to test
hypothesis about a possible mechanism. In the case of CTL killing model, I used a simple kinetic model
to estimate the range for CTL killing rate, and showed that previous contacts with T cells change the
probability of a target cell to die. This result shows that the killing process has memory, i.e. previous
contacts influence fate of target cells.
In the field of mathematical modelling one often faces a lack of experimental data, but in certain
cases one may perform simulations in order to see the qualitative behaviour of the system and to
suggest new experiments in this direction. In our model of interacting GCs, I compare the development
of GCs in the early and the late environments and hypothesize that early GCs may suppress the later
ones. A more precise model can be based on experiments in which individual GC kinetics is measured
depending on the concentration of antigen specific antibodies if artificially injected.
Biological systems consist of objects which perform their function at different scales. This demands
to construct multi-scale models and to implement a variety of approaches. In the GC model, I use ODE
to describe cell populations and antibody concentrations, where spatial aspects were not considered.
However, modelling of cell clustering demands description of molecular diffusion and cell behaviour
defined by its location. Multiscale modelling is a developing branch of computational biology, however,
there are no established standard frameworks for simulations. In contrast, ODE models may utilise
any of available ODE solvers implemented in a variety of programming languages. Construction of
3D agent-based models involves a high number of assumptions about details which are neglected in
population-based ODE models. It results in a challenge of model parametrisation and extensive litera-
ture analysis for available data. In addition, a modeller has to make a decision on the question about
which processes are to be included into the model and which of them can be neglected. Although it
does not represent any technical knowledge about mathematical modelling, this is a very important
aspect which may influence the direction of model development and demands effective communication
with clinical experts. In this project, I developed a framework which includes efficient collision detec-
tion between migrating cells, description of chemokine diffusion and its internalisation due to binding
86
to the receptors. Although it may reproduce cell clustering around cells which secrete the chemokine,
there is a number of possible improvements in terms of implementation. Firstly, the collision algorithm
and diffusion solver can be parallelised in order to handle bigger systems with more participating cells
and to describe chemokine profiles with higher precision. Secondly, the chemokine concentration could
be described using finite element method. This approach is more flexible in terms of form of simulated
domain, i.e. it allows to more easily adapt PDE to domains of arbitrary shape, and, hence, to incorpo-
rate more details about organ structure. Another benefit of using finite element method is more precise
modelling of chemokine secretion, because a node of the finite element mesh can be positioned exactly
to the location of the secreting cell.
Additionally, the simulation outcome is not represented by a single measurable value, but by the
list of cell positions and chemokine concentrations instead. Here we face the problem of comparison of
the model simulation with patient biopsies which is to be resolved in the future. The kinetic rates of
receptor dynamics and chemokine binding measured for CXCR5-CXCL13 receptor-ligand pair or similar
molecules allowed us to estimate characteristics of clustering, such as trapping distances or receptor
densities at which gradient inversion is possible. The missing part from experimental support is in the
information about stroma activation. The knowledge of critical contacts frequency needed for stroma
differentiation would allow to model cluster formation more precisely in the condition of lymphocyte
influx into the tissue.
Apart of fundamental interest, mathematical modelling of immune responses might have implica-
tions in clinics. Simulation of GC reactions might help in optimization of immunization conditions in
order to boost the immune response and to select more affine B cell clones, since there is a way to in-
fluence the selection process via injections of specific antibodies. Although the GC model has not been
applied to any patient data yet, the other two projects, namely, the model of TLO development and the
model of CTL killing, were developed in close communication with our clinical partners.
Immunosuppressive therapy is an approach to control conditions of kidney transplants. The usage of
anti-CD20 antibodies (e.g. Rituximab) results in depletion of the B cell population. Although this help
to decrease graft damage, which is caused by antibody-mediated response, the suppressed immune
system can not efficiently eliminate infected or cancer cells. In order to diminish side effects of the
immunosupperssion, the dosage of the treatment can be controlled according to graft biopsy results.
For example, if there will be a direct evidence of the contribution of TLOs in graft rejection in human,
mathematical modelling might provide suggestions for the treatment in order to avoid formation of this
structures. In this case, the agent-based model might predict the probability for stromal cell activation
on the basis of the lymphocyte densities in biopsies of transplanted grafts, which would result in a
suggestion about increase or decrease of treatment dose. Unfortunately, we lack the information about
stroma activation mechanisms. Additional experiments, which are directed on the quantification of
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stroma activation for different lymphocytes densities, could help to fit the agent-based model in order
to generate biopsy-based predictions.
TLOs are observed not only in transplantation, but in autoimmune diseases, e.g. rheumatoid arthri-
tis. These immune cell clusters were shown to be a source of auto-antigenic cells. If the treatment
directed against TLO formation can be used for such conditions, the information about cluster stability
may be taken into consideration during adjustment of anti-chemokine or receptor antagonist therapies.
Injection of receptor antagonists can block lymphocyte navigation, which would result in cluster disso-
lution. Ideally, the outcome of the model would be suggestion of a dose of therapeutic agent, which can
block long-range cell interactions governed by chemokine gradients. If this kind of therapy could be
used together with or substitute anti-CD20 treatment, which is currently used in many cases, patients
might benefit because there will be reduced depletion of the whole B cell population. Moreover, local
administration of the therapeutic agent would prevent only cell clustering in the graft.
Although the current model does not provide predictions about TLO formation in the context of
patient tissue and can not be used in clinics right now, with this work I hope to provoke new experiments
in order to identify the role of immune cell clusters in graft rejection and other pathological conditions.
Another example for application of mathematical modelling is CTL-based therapy. Adoptive transfer
of T cells is a very promising approach which can be used to treat cancer or infection diseases. Quan-
titative characterisation of CTL killing efficiency might help to optimise therapy effect and its costs.
In order to know, how many cells are needed to be delivered to a patient, one needs to estimate the
killing rate by CTLs in vivo. Mathematical models of killing kinetics can provide these estimations and
predict population dynamics in time. Besides killing rate estimations, I show that multiple contacts can
dramatically increase probability of infected cells to die. This result raises a question of mechanisms of
CTL killing which is very interesting in the context of fundamental T cell biology.
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AAnalysis of GC size in spleen samples
The power of immune response varies among different immunisation conditions, and antibody feedback
might be changed too, what may influence GC size.
To compare germinal centre size in different immunisation conditions we analysed microscopy im-
ages of spleen samples from mice which were immunised only intravenously or intravenously and into
food pad. We used the Python interface to OpenCV computer vision library[25].
The samples were stained for PNA-binding GC B cells (green) and for surface immunoglobulin IgD,
which is expressed at the surface of naive B cells in B cell follicles (red), see fig. A.1. The median filter
was applied to the images in order to decrease noise and to delete small nonspecific staining areas.
After then images were subjected to thresholding with the threshold value chosen according to visual
evaluation of the result and applied to all images. The GCs area was measured using ImageJ[2] by
manually picking specifically stained green areas in the red follicles.
Comparison of GC sizes from samples coded as 1-4 for intravenous immunisation and 5-7 for intra-
venous and foot pad immunisation did not show any significant difference (Wilcoxon test with p-value
0.54). Experiments with other form of immunisation like intraperitoneal or comparison between or-
gans, for example, GC sizes in spleen versus LNs, may help to estimate the impact of antibodies onto
GC reaction.
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Figure A.1: Processed image of the spleen splice. Green arease correspond to GC B cells
(PNA) and is shown separately at the right image. Red regions are B cell follicles stained
with anti-IgD antibodies. The samples contains nonspecific staining, hence GC areas were
selected manually.
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Figure A.2: GC size in i.v. immunisation (1-4 experiments) and i.v. + footpad (5-7)
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